Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Visual performance of senofilcon A with and without a new UV/HEV -filter 
Protocol CR-6463
Version: 3.0
Date: [ADDRESS_905885] 2021
Investigational Products: senofilcon A soft contact [CONTACT_340366]/HEV -filter
Keywords: Sphere platform, senofilc on A with a new UV/HEV -filter, senofilcon A without a 
new UV/HEV -filter (ACUVUE OASYS 1 -Day), daily wear, daily disposable, non -dispensing, 
Cambridge Research Systems Metropsis software, photo pic and mesopic contras t sensitivity 
under broadband light conditions, photopic resolu tion acuity under broadband light conditions.
Statement of Compliance to protocol, GC P and applicable regulatory guidelines:
This trial will be conducted in compliance w ith the proto col, ISO 1 4155 :2020 ,1the 
International Council for Harmonization Good Clinical Practice E6 (R2) (ICH GCP) ,2
Declaration of Helsinki ,3and all applicable regulatory requirements.
Confidentiality Statement:
This document contains confidential infor mation, which should not be copi[INVESTIGATOR_530], refe rred to, 
released or published without written approval  from [COMPANY_012] Vision Care, Inc. The 
information may not be disclosed to others except to the extent necessary to obtain Institutional 
Review Board/Independent Eth ics Committee approval and in formed consent, or as required 
by [CONTACT_19543], Federal and State  Laws, as applicable. Persons to wh om this information is 
disclosed must be informed that this informatio n is privileged and confidential and that it 
should not be further disclosed without the written permission of [COMPANY_012] Vision 
Care, Inc. Any supplemental information that may b e added to this document is also 
confidential and proprieta ry to [COMPANY_012] Vision Care, Inc. and must be kept in 
confidence in the same manner as t he contents of this document.
CR-6463, v3.0
Page 1 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
TABLE OF CONTENTS
PROTOCOL TITLE, NUMBER, VERSION AND DATE ................................ ...................... 7 
SPONSOR NAME [CONTACT_71191] ................................ ................................ ....................... 7 
MEDICAL MONITOR ................................ ................................ ................................ ............. 7 
AUTHORIZED SIGNATURES ................................ ................................ ............................... 8 
CHANGE HISTORY ................................ ................................ ................................ .............. 10 
SYNOPSIS ................................ ................................ ................................ .............................. 13 
COMMONLY USED ABBREVIATIONS, ACRONYMS AND DEFINI TIONS OF TERMS
................................ ................................ ................................ ................................ ................. 22 
1. INTRODUCTION A ND BACKGROUND ................................ ................................ ...23 
1.1. Name [CONTACT_126139] ................................ ................ 29 
1.2. Intended Use of Investigational Products ................................ ................................ .29 
1.3. Summ ary of Findings from Nonclinical Studies ................................ ...................... 29 
1.4. Summary of Known Risks and Benefits to Human Subjects ................................ ...29 
1.5. Relevant Literature References and Prior Cl inical Data Relevant to Proposed Clinical 
Study ……………………………………………………………………………………...[ADDRESS_905886] ARTICLE ALLOCATION AND MASKING ................................ ..................... 39 
CR-6463, v3.0
Page 2 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
5.1. Test Article Allocation ................................ ................................ ............................. 39 
5.2. Masking ................................ ................................ ................................ .................... 40 
5.3. Procedures for Maintaining and Breaking the Masking ................................ ........... 40 
6. STUDY INTERVENTION ................................ ................................ ............................. 40 
6.1. Ancillary Supplies/Products ................................ ................................ ..................... [ADDRESS_905887] Articles ................................ ................................ ................ 42 
7. STUDY EVALUATIONS ................................ ................................ .............................. 43 
7.1. Time and Event Schedule ................................ ................................ ......................... 43 
7.2. Detailed Study Procedures ................................ ................................ ....................... 44 
PHASE 1:  VISIT 1 ................................ ................................ ................................ ......... 44 
PHASE 2:  VISIT 1 ................................ ................................ ................................ ......... 49 
FINAL EVALUATION ................................ ................................ ................................ ..56 
7.3. Unscheduled Visits ................................ ................................ ................................ ...56 
7.4. Laboratory Procedures ................................ ................................ ............................. 58 
8. SUBJECTS COMPLETION/WITHDRAWAL ................................ .............................. 58 
8.1. Completion Criteria ................................ ................................ ................................ ..58 
8.2. Withdrawal/Discontinuation from the S tudy ................................ ........................... 58 
9. PRE-STUDY AND CONCOMITANT INTERVENTION/MEDICATION ................. [ADDRESS_905888] AINTS .............. 62 
13. ADVERSE EVENTS ................................ ................................ ................................ ...63 
13.1.  Definitions and Classifications ................................ ................................ ............. 63 
13.2.  Assessing Adverse Events ................................ ................................ .................... 65 
13.2.1.  Causality Assessment ................................ ................................ .................... 66 
13.2.2.  Severity Assessment ................................ ................................ ...................... 66 
13.3.  Documentation and Follow -Up of Adverse Events ................................ .............. 66 
13.4.  Reporting Adverse Events ................................ ................................ .................... 68 
13.4.1.  Report ing Adverse Events to Sponsor ................................ .......................... 68 
CR-6463, v3.0
Page 3 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
13.4.2.  Reporting Adverse Events to the Res ponsible IEC/IRB and Health Authoritie s
………………………………………………………………………………[ADDRESS_905889] KEEPI[INVESTIGATOR_1645]/ARCHIVING ................................ 75 
15.1.  Electronic Case Report Form/Data Collection ................................ ..................... [ADDRESS_905890] ................................ ................................ ................................ ......76 
15.3.  Trial Registration on ClinicalTrials.gov ................................ ............................... 76 
16. DATA MANAGEMENT ................................ ................................ ............................. 77 
16.1.  Access to Source Data/Document ................................ ................................ ........ 77 
16.2.  Confidentiality of Information ................................ ................................ .............. 77 
16.3.  Data Quality Assurance ................................ ................................ ........................ 77 
16.4.  Data Monitoring Committee (DMC) ................................ ................................ ....[ADDRESS_905891] (IEC/IRB) .......... [ADDRESS_905892] RETENTION ................................ ................................ ................ 81 
20. FINANCIAL CONSIDERATIONS ................................ ................................ ............ 82 
21. PUBLICATION ................................ ................................ ................................ ........... 82 
CR-6463, v3.0
Page 4 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
22. REFERENCES ................................ ................................ ................................ ............ 82 
APPENDIX A: PATIENT REPORTED OUTCOMES (STUDY QUESTI ONNAIRES) .....86 
APPENDIX B: PATIENT INSTRUCTION GUIDE ................................ ............................. 87 
APPENDIX C: PACKAGE INSERT (APPROVED PRODUCT) ................................ ......... 88 
APPENDIX D: ................................ ....[ADDRESS_905893] REPORTED OCULAR SYMPTOMS/PROBLEMS ........................ 124 
 DETERMINATION OF DISTANCE SPHEROCYLINDRICAL REFRACTIONS
................................ ................................ ................................ ................................ ............... 126 
 BIOM ICROSCOPY SCALE ................................ ................................ .............. 132 
 DISTANCE AND NEAR VISUAL ACUITY EVALUATION ......................... 138 
APPENDIX E: ACCEPTANCE OF THE METROPSIS SYSTEM ................................ ....143 
APPENDIX F : DETERMINATION OF EYE DOMINANCE ................................ ............ 148 
APPENDIX G: GUIDANCE FOR INITIAL LENS POWER ................................ ............. 149 
APPENDIX H: METROPSIS WORK AID ................................ ................................ ......... 150 
APPENDIX I: METROPSIS AND GLARE SOURCE SPECIFICS ................................ ...168 
APPENDIX J: GUIDELINES F OR COVID -19 RISK MITIGATION ............................... 170 
PROTOCOL COMPLIANCE INVESTIGATOR(S) SIGNATURE [CONTACT_1783] ........................ [ADDRESS_905894] OF TABLES
Table 1: Anticipated tim ing of visual performance testing. ................................ ................... 38 
Table 2: Test Articles for Phase 2 ................................ ................................ ........................... 40 
Table 3: Ancillary Supplies for Phas e 2................................ ................................ ................. 41 
Table 4: Time and Events ................................ ................................ ................................ ....... 43 
Table 5: Disallowed systemic med ications ................................ ................................ ............. 60 
Table 6: Di sallowed systemic antihistamines ................................ ................................ ......... 60 
Table 7: Examples of major and minor protocol deviations ................................ ................... 61 
Table 8:  Descri ptive Summary of Log MAR Visual Acuity and AULCSF from qCSF testing 
based on Historical Data –Completed Per Protocol Subjects ................................ ................ 70 
Table 9:  Power Analysis for the Primary and Secondary Hypotheses (Superiority Testin g)[ADDRESS_905895] OF FIGURES
Figure 1:  Study Flowchart ………………………................................................... ............... .20 
Figure 2:  Relevant ocular transmission and absorbance.  ................................ ..................... 23 
Figure 3:  Scatter and wavelength.  ................................ ................................ ........................ 24 
CR-6463, v3.0
Page 5 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Figure 4:  Emission spectra various light sources.  ................................ ................................ 25 
Figure 5: Experimental Set -up................................. ................................ ............................... 27 
Figure 6: Broadband light (glare) source.  ................................ ................................ ............. 27 
Figure 7:  Example of the Metropsis testing system ................................ ............................... 28 
Figure 8: Disability glare and chromatic contrast measurements ................................ ........... 31 
Figure 9: Two -point light threshold test ................................ ................................ ................. 31 
Figure 10: Halo and starburst measurements ................................ ................................ .......... 32 
Figure 11: Representative image of the primary and secondary packaging for Pha se 2. ....... 42 
 
CR-6463, v3.0
Page 6 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
PROTOCOL TITLE, NUMBER, VERSION  AND DATE  
Title: Visual performance of senofilcon A with and without a new UV/HEV -filter 
Protocol Number: CR-6463
Versi on:3.0
Date: 30August 2021
SPONSOR NAME [CONTACT_126140] S 
[COMPANY_012] Vision Care , Inc.(JJVC)
[ADDRESS_905896] be notified by [CONTACT_93822]/site by e -mail or teleph one 
within 24 hours of learning of a Serious Adverse Event. The Medical Monitor may be contac ted 
during business hours for adverse event questions. General study related questions should b e
directed towards your assigned clinical research associate.
The M edical Monitoring P lan is maintained as a separate document and inc luded in the Trial 
Master File.
 
CR-6463, v3.0
Page 7 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Reviewer See Electronic Signature [CONTACT_35594]-6463, v3.0
Page 9 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
SYNOPSIS 
Protocol Title Visual performance of senofilcon A with and without a new 
UV/HEV-filter 
Sponsor JJVC, [ADDRESS_905897], Jacksonville, FL  [ZIP_CODE]
Clinical Phase Clinical trial phase: feasibility
Design control phase: confirmatory phase
Trial Registration This study will be registered on ClinicalTrials.gov by [CONTACT_670594](s) Investigational Products: Test lens: senofilcon A with a new
ultraviolet (UV) and High Energy Visible (HEV) light f ilter.
Approved Products: Control lens: ACUVUE OASYS 1 -Day 
(AO1D) (senofilcon A without a new UV/HEV-filter)
Wear and Replacement 
SchedulesWear Schedule: daily wear
Replacement Schedule: da ily (non-dispensing study)
Objectives The intent of this study is to demonstrate that the Test lens 
provide s visual benefits under cond itions for which it was 
designed.
Primary Objectives : The p rimary objective is to evaluate the 
visual performance characteristics of a new HEV -filter under 
conditions of an HEV-rich ecologically-valid light source.
Study Endpoints Phase 1: 
xPrimary endpo int(s): photopic and mesopic contrast
sensitivity with and without glare.
Phase 2:
xPrimary endpoint(s):  Photopic resolution acuity
xSecondary endpoint(s): Mesopic contrast sensitivity,
photopic contrast sensitivity
xAll primary and secondary endpoints will be assessed
in the presence of an ecologically- valid broadband
light source that emulates na tural sunlight in spectral
content across the visible spectrum.
CR-6463, v3.0
Page 13 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Study Design This study will occur in two non-dispensing phases:
Phase 1: 
oApproximately [ADDRESS_905898] sensitivity about 0.1 log units at 6 cpd (ANSI
Z80.12 –2007) under both photopic and mesopic
conditions. This phase is a non- dispensing, non-
randomized, controlled evaluation where subject s will
wear their habitual co ntact lenses during testing.
Subjects will be enrolled for approximately 1 hour.
Phase 2: 
oApproximately [ADDRESS_905899] will be contralaterally fitted with the two study
articles during the single wearing period.  Subjects will
be enrolled for approximately 3 hours.
See the flow chart at the end of the synopsis table for the 
schematic of the study visits and procedures of main 
observations (Figure 1).
Sample Size Phase 1: 
oUp to 24 subjects will be enrolled to help ensure that
20 subjects complete phase 1 as cohort.
Phase 2:  
oUp to 66 subjects will be enrolled to help ens ure that
60 subjects complete phase 2 as cohort.
Study Duration Phase 1:
oThe enrollment period will last approximately 1 week.
Phase 2:
oThe enrollment period will last approximately 8
weeks.
There will be an approximately one week pause between 
phase 1 and phase 2 for an interim analyses.  Since this is a 
single -visit, non- dispensing study, the entire study duration
(phase 1 + interim analysis + phase 2) will las t approximately 
10 weeks.
CR-6463, v3.0
Page 14 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Anticipated Study 
PopulationSubjects must be habitual wear ers of silicone hydrogel contact 
[CONTACT_486748] a daily wear basis.  Subjects can be of any 
gender, race, and ethnicity that meet the eligibility criteria.  Subjects enro
lling in phase [ADDRESS_905900] the 
same eligibility criteria except where note d.
Subjects who participate in phase 1 of the study will not 
participate in phase 2 of the study.
Eligibility Criteria –
Inclusion –PHASE 1Phase [ADDRESS_905901] udy:
Inclusion Criteria following Screening
The subject must:
1.Read, understand, and sign the STATEMENT OF
INFORMED CONSENT and receive a fully executed
copy of the form.
2. Appear able and willing to adhere to the instructions
set forth in this clinical protocol.
3. Be between 18- 39 (inclusive) years of age at the time
of screening.
4. By [CONTACT_6270]- report, habitually wear spherical silicone
hydrogel soft contact [CONTACT_35482] a daily
reusable or daily di sposable wear modality (i.e. not
extended wear modality). Habitual wear is defined as
a minimum of [ADDRESS_905902] be
between -1.00 D and - 6.00 D (inclusive) in each eye.
Inclusion Criteria following Baseline Evaluation
7. H abitual contact [CONTACT_670595] 20/20
acuity OD and OS
CR-6463, v3.0
Page 15 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Eligibility Criteria –
Inclusion –PHASE 2Phase [ADDRESS_905903] satisfy all of the following criteria to be enrolled in the study:
Inclusion Criteria 
following Screening
The subject must:
1. Read, understand, and sign the STATEMENT OF
INFORMED CONSENT and receive a fully executed
copy of the form.
2. Appear able an d willing to adhere to the instructions
set forth in this clinical protocol.
3. Be between 18 and 70 (inclusive) years of age at the
time of screening.
4. By [CONTACT_6270]-report, habitually wear spherical silicone
hydrogel soft contact [CONTACT_35482] a daily
reusable or daily disposable wear modality (i.e. not
extended wear modality). Habitual wear is defined as
a minimum of [ADDRESS_905904]’s vertex -
corrected distance refraction must be between - 1.00 D
and -6.00 D (inclusive) in each eye.
7. The magnitude of the cylindrical compone nt of the
subject’s vertex -corrected distance refraction must be
between 0.00 D and 1.00 D (inclusive) in each eye.
8. The best corrected, monocular, distance visual ac uity
must be 20/25 or better in each eye.
CR-6463, v3.0
Page 16 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Eligibility Criteria –
Exclusion –PHASE 1Phase 1 Exclusion Criteria
Potential subjects who meet any of the following criteria will be excluded from participating in the study: 
Exclusion Criteria 
following Screening
The subject must not:
1. Be currently pregnant or lactating.
2. Be currently using any ocul ar medications or have any
ocular infection of any type.
3. By [CONTACT_6270]- report, have any ocular or systemic disease,
allergies, infection, or use of medication that might
contraindicate or interfere with contact [CONTACT_13279], or
otherwise compromise study endpoints , including
infectious disease (e.g., hepatitis, tuberculosis),
contagious immunosuppressive disease (e.g., Human
Immunodeficiency Virus [ HIV]), autoimmune disease
(e.g. rheumatoid arthritis, Sjögre n’s syndrome), or
history of serious mental illness or sei zures. See
section 9.[ADDRESS_905905] habitually worn rigid gas perm eable (RGP)
lenses, orthokerato logy lenses, or hybrid lenses (e.g.
SynergEyes, SoftPerm) within the past [ADDRESS_905906]
clinical trial within 30 days prior to study enrollment.
8.Be an employee (e.g., Investigator, Coordinator,
Technician) or immediate family member of anemployee (including partner, child, parent,
grandparent, grandchild o r sibling of the employee or
their spouse) of the clinical site.
Exclusion Criteria following Baseline Evaluation
The subject must not:
9.Have clinically significant (grade 3 or higher on the
FDA grading scale) slit lamp findings (e.g., corneal
edema, neova scularization or staining, tarsal
abnormalities or bulbar inj ection) or other corneal or
ocular disease or abnorma lities that contraindicate
contact [CONTACT_670596] (including entropi[INVESTIGATOR_2394], ectropi[INVESTIGATOR_2394], chalazia,
recurrent styes, glaucoma , history of recurrent corneal
CR-6463, v3.0
Page 17 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
erosions, aphakia, moderate or above corneal
distortion, herpetic keratitis).
10. Have a history of strabismus or amblyopia.
11.Have fluctuations in vision  due to clinically significant
dry eye or other ocular conditions.
12. Have had any ocular or in traocular surgery (e.g., radial
keratotomy, PRK, LASIK, ir idotomy, retinal laser
photocoagulation, etc.).
13. Have signs of a contact [CONTACT_13293]- related corneal
inflammatory event (e.g., past peripheral ulcer or
round peripheral scar).
14. Have a history of eyelid injur y, surgery or procedure
that resulted in abnormal eyelid position or movement.
CR-6463, v3.0
Page 18 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Eligibility Criteria –
Exclusion –PHASE 2Phase 2 Exclusion Criteria
Potential subjects who meet any of the following criteria will be exclu
ded from participating in the study:
Exclusion Criteria following Screening
The subject mus t not:
1. Be currently pregnant or lactating.
2.Be currently using any ocu lar medications or have any
ocular infection of any type.
3. By [CONTACT_6270]-report, have any ocular or systemic disease,
allergies, infect ion, or use of medication that might
contraindicate or int erfere with contact [CONTACT_13279], or
otherwise compromise study endpoints, including
infectious disease (e.g., hepatitis, tuberculosis),
contagious immunosuppressive disease (e.g., Human
Immunodeficiency Virus [ HIV]), autoimmune disease
(e.g. rheumatoid arthr itis, Sjögren’s syndrome), or
history of se rious mental illness or seizures. See
section 9.[ADDRESS_905907] habitually worn rigid gas perm eable (RGP)
lenses, orthokeratology lenses, or hybrid lenses (e.g.
SynergEyes, SoftPerm) within the past [ADDRESS_905908]
clinical trial within 30 days prior to study enrollment.
8.Be an employee (e.g., Investigator, Coordinator,
Technician) or immediate family member o f an
employee (including partner, c hild, parent,
grandparent, grandchild or sibling of the em ployee or
their spouse) of the clinical site.
Exclusion Criteria following Baseline Evaluation
The subject must not:
9. Have clinically significant (grade 3 or highe r on the
FDA grading scale) slit la mp findings (e.g., corneal
edema, neovascularization or st aining, tarsal
abnormalities or bulbar inj ection) or other corneal or
ocular disease or abnorma lities that contraindicate
contact [CONTACT_670597] (including ent ropi[INVESTIGATOR_2394], ectropi[INVESTIGATOR_2394], chalazia,
recurrent styes, glaucoma, history of recurrent corneal
CR-6463, v3.0
Page 19 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
erosions, aphakia, moderate or above corneal 
distortion, herpetic keratitis).
10. Have a history of strabismus or amblyopia.
11. Have fluctuations in vision due to clinically sign ificant
dry eye or other ocular conditions.
12. Have had any ocular or intraocular surgery (e.g., radial
keratotomy, PRK, LASIK, iridotomy, retinal laser
photocoagulation, etc.).
13. Have signs of a contact [CONTACT_13293]- related corneal
inflammatory event (e.g., past peri pheral ulcer or
round peripheral scar).
14. Have a history of eyelid injury, surgery or procedure
that resulted in abnormal eyelid position or movement.
Disallowed 
Medications/Interventions Subjects taking any ocular medication will not be allowed to 
partici pate.
See section 9.[ADDRESS_905909] 
(UADE) or Serious Adverse Event (SAE) for which a causal 
relationship to a test article cannot be ruled out, will result in 
stoppi[INVESTIGATOR_71144]. In the 
event of a UADE or SAE, the Sponsor Medical Monitor may 
unmask the treatment regimen of subject(s) and may discuss 
this with the Principal Investig ator before any further subjects 
are enrolled.
Ancillary Supplies/ Study-
Specific MaterialsCambridge Research System Metropsis software will be used 
for clinical measurements.  In addition, an ecologically- valid 
broadband glare source that emulates natural sunlight in 
spectral content across the visi ble spectrum will be used.  
RevitaLens will be used to  return any problematic lenses to
the Sponsor.
Principal Investigator(s) 
and Study Institution(s)/Site(s)A full list of Principal Investigators, clinical sites, and 
institutions is kept separately from the Study Protocol and is 
included in the study Trial Master File.
CR-6463, v3.0
Page 20 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Figure 1: Study Flowchart
80-90 Subjects
Available powers: -1.[ADDRESS_905910] lenses worn as daily wear
Excludes wearers of toric, monovision, multifocal, extended wear
Age 18-70
PHASE 2 
(60-66 subjects, 18-70 years old)
Informed Consent
Eligibility Criteria
Baseline Information
¾ Habitual lens type, modality
¾ Subjective refraction
¾ Eye dominancy
¾ Ocular physiology
Visual Performance Testing
¾ Photopic resolu ion acuity: Landolt C ’s will be presented with and 
without a broadband glare source
¾ Photopic contrast sensitivity: with and without a broadband glare source
¾ Mesopic contrast sensitivity: with and without a broadband glare source
Lens Removal and Ocular Physiology
¾ The lenses will be removed and ocular physiology assessed.
Final EvaluationPHASE 1 
(20-24 Subjects, 18-39 years old)
Informed Consent
Eligibility Criteria
Baseline Information
¾ Habitual lens type, modality
¾ Visual acuity
¾ Ocular physiology
Visual Performance Testing
Photopic and mesopic contrast sensitivity 
at 6 cpd with and without a broadband 
glare source.Trial Lens Fitting
¾ Subjects will be randomly assigned a test lens on one eye and a control 
lens on the other eye
¾ Modify lens powers to obtain 0.00 D spherical over-refraction
10-Minute Evaluation
¾ Symptoms
¾ Fitting characteristics, VA
¾ For release, the lenses must provide:
¾ Appropriate fitting characteristics on both eyes
¾ 20/30 or better vision in both eyes
¾ Investigator approvalInterim Analysis
CR-6463, v3.0
Page 21 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
COMMONLY USED ABBREVIATIONS , ACRONYMS  AND DEFINITIONS OF 
TERMS  
ADE Adverse Device Effect
ADHD Attention Deficit Hyperactivity Disorder
AE Adverse Even t/Adverse Experience
AO1D ACUVUE OASYS 1-Day
BSCVA Best Spectacle Corrected Visual Acuity
CFR Code of Federal Regulations
CLUE Contact [CONTACT_670598]
D Diopter
DMC Data Monitoring Committee
eCRF Electronic Case Report Form
EDC Electronic Data Capture
FDA Food and Drug Administration
GCP Good Clinical Practice
HEV High E nergy Visible light
HIPAA Health Insurance Portability an d Accountability Act
HIV Human I mmunodeficiency Virus
IB Investigator’s Brochure
ICH The International Council for Harmonization
IEC Independent Ethics Com mittee
IRB Institutional Review Board
ISO International Organization for Standardization
ITT Intent -to-Treat
JJVC [COMPANY_012] Vision Care, Inc.
LASIK Laser -Assisted in Situ Keratomileusis
LED Light -Emitting Diode
OD Right Eye
OS Left Eye
OU Both Eyes
PIG Patient I nstruction Guide
PQC Product Quality Complaint
PRK Photorefractive Keratectomy
PRO Patient Reported Outcome
QA Quality Assurance
SAE Serious Adverse Event/Serious Adverse Experience
SAP Statistical Analysis Pla n
SAS Statistical Analysis System
SD Standard Deviation
CR-6463, v3.0
Page 22 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
UADE Unanticipated Adverse Devi ce Effect
[LOCATION_003]DE Unanticipated Serious Adverse Device Effect
UV Ultraviolet radiation
VA Visual Acuity
1.INTRODUCTION AND BACKGROUND
Energy from the sun supports almost all of life on planet earth .  Earth exists in a “Goldilocks’ 
zone .”If we were any c loser to the sun, we would overheat like Venus and if we were any 
farther from the sun, we would freeze like Ma rs.  Discussions about global warming that could 
cause ecological collap se revolve arou nd overall atmospheric temperatures that vary by [CONTACT_108774] a 
few degrees.  The biological response to light from the sun is similar.   Light is both essential 
to our biology but in excess drives many deleterious effects especi ally to our most lig ht
responsive s ystem.  The visual system evolved to respond to light from about 380-780nm but 
also evolved to carefully manage how those wavebands are processed by [CONTACT_670599].  
One reason is that these wavelengths are not all eq ually capable of bio logical damage.
A wide body of diverse empi[INVESTIGATOR_670584] l ight from about [ADDRESS_905911] 
damaging to retinal tissue because (1) it reaches the retina  and is  not significantly absorbed by 
[CONTACT_670600] (2) i t still retains enou gh energy to in itiate photochemical damage (e.g., 
convert inert oxygen in to reactive forms) and (3) fits the action spectrum of retinal 
photosensitizers (like lipofuscin).5-9Lipofuscin is thou ght to contribute to retinal 
maculo pathies due to generation of singlet oxygen which is abund antly generated by [CONTACT_670601] [ADDRESS_905912] 
function (ISO 8980 -3).  The terms blue-light hazard function and HEV largely involve the 
same wavelengths.[ADDRESS_905913] light is dominant in the atmosphere (e.g., blue skylight ) followin g Rayleigh’s 
simpl ified equation (ݎ݁ݐݐܽܿܵ∝ଵ
ఒర).The danger, however, posed by [CONTACT_670602] V light to ocular tissue
CR-6463, v3.0
Page 23 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
specifically is the foundation of many safety standards (e.g., ANSI Z80.3 -2015, Z87.1 -2015 or 
ISO-8980 -3).    Hence, the problem: how does a given species both take advan tage of a plentiful 
source o f light (e.g., to enhance color vision) while simultaneously obviating the damage from 
such an energetic source of radiation?   A parallel problem exists.  Short -wave light enhances 
visual performance, by [CONTACT_670603], expanding the range of color vision.  HEV, however, 
simultaneously degrades visu al performance because lenticular scatter is inversely 
proportional to wavelength ( Figure 3)13,[ADDRESS_905914] such light excessively 
degrade the visual signal or damage the system?  The adaptive strategy, adopted across an 
extreme variety of species (particular ly those that share a similar nic he) appears to have been 
a strategic use of filtering.  Such a strategy is  not surprising.  Plants have used screening 
pi[INVESTIGATOR_670585] e effects of light for most of th e history of the planet (starting 
with blue -green algae) .15,16The amount of melanin in the human skin varies by [CONTACT_670604] (balancing protecting folic acid stores 
with the need to synthesize Vitamin D) .17   A number of species evolved yellow corneas (e.g., 
Prairie dogs, Perch) o r yellow oil droplets (many species of bird) to modulate HEV light 
incident on their photoreceptors.[ADDRESS_905915] studied the 
immediate functional significance of intraocular filtering .19Walls and Judd (1933) first 
CR-6463, v3.0
Page 24 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
however, which contains very little or no HEV light.  For example, the CSV [ADDRESS_905916] of the 
variance in real world vision (and that much on ly when age, a significant covariate, was 
added).25
So, how can we do better?
The key is to meas ure variables such as CSF and acuity is to measure them under conditions 
that more closely resemble the conditions that we are trying to predict.  Our plan w ould be to 
measure CSF and acuity with glare (at photopic and low -light, mesopic, levels) under lig hting 
conditions designed to closely match the spec trum of everyday life, e.g., real daylight. Natural 
HEV light is also consistently experienced indoors th roughout the day since most residential 
windows transmit 56 -90% visible light while most commercial windows transmit 13 -58% .[ADDRESS_905917] lens.
We will achieve this objective through two aims :
1.Usean ecologically -valid light (glare) source with the Metropsis visual function
assessment sys tem (Cambridge Research Systems, [COMPANY_002]ster ME2 4BH, United
Kingdom ).  The standard glare source of the Metropsis system emits wavelengths
similar to a whi te LED (Figure 4 top right), and thus is not appropriate for testing the
HEV -filtering properties of t he Test lens.  The light source for this study will be a n
annular ring placed between the s ubject and the Metropsis screen ( Figure 5,Figure
6).27The g lare source and its approximate intensity at the plane of the eye are
calculated safe for use based on ANSI Z136.1 –2014 ( .[ADDRESS_905918]
testing and up to 150 minutes of photopic re solution acuity testing during a single
experimental day.
CR-6463, v3.0
Page 26 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
The l ight itself will be generated by a xenon source with a neutral density wedge to control 
intensity and chromatic  filters to create t he spectrum.  The emitted wavelengths will mimic 
mid-day sunlight, while the intensity of the light source will achieve both anapproximate 0.[ADDRESS_905919] during testin g.  The Metropsis system is well -accepted in the ophthalmic community 
(Figure 7,Appendix E).  Furtherinformation about the Metropsis system and its intended use 
in this study can be found in the Work Aid.  
CR-6463, v3.0
Page 27 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
1.Within -subject evaluation of the impact of an HEV -absorbing contact [CONTACT_670605] a stan dard transparent contact [CONTACT_670606] a broadband glare source (n = 60).
Finally, the statement that “There is no accepted standardized method for glare testing” is 
largely true.29There are several ISO standards that mention glare (e.g., 9358:1 194, [ZIP_CODE] -
6:2014, [ZIP_CODE]:2008), seve ral CIE documents (e.g., 17 -22-098, 17 -22-103, 146:2002), several 
IES documents ( https://www.ies.org/?s=Glare ), and multiple ANSI standards that mention 
glare ( https://webstore.ansi.org/Search/Find?in=1&st=glare ) and none of them mention how a 
glare source should be consistently incorporated  into visual performance testing.  How close 
should the glare source be to the target?  How close should th e glare source be to the eye?  
How many glare sources should there be?  How bright should the glare sources be?  What 
should the spectral emission of the glare sources be?  These uncertainties inevitably lead to 
inconsis tencies from instruments to instrume nts,and subsequently, from studies to studies.  
ANSI Z80.[ADDRESS_905920] sensitivity by [CONTACT_2902] 0.1 log units at 6 cpd.  
The number of subjects that constitute “a small pi[INVESTIGATOR_48085] t” is debatable.  The acceptable standard 
deviation that defines “about” 0.[ADDRESS_905921] ure glare testing instruments (e.g., M&S Technologies ( Niles, IL , US), and Metropsis 
by [CONTACT_670607] ([COMPANY_002]ster, [LOCATION_006])) have adopted this standard for all glare 
testing and this will be implemented in the stu dy.30-33
CR-6463, v3.0
Page 28 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
1.1. Name [CONTACT_670628] 1:  Not applicable.  Subjects will wear their habitual contact [CONTACT_13276].
Phase 2: This study will test one(1)Test senofilcon A design prototype containing a new 
UV/HEV -filter  againstone(1)Control commercially available marketed product (ACUVUE 
OASYS®1-Day) which is also made from senofilcon A material but does not contain the new
UV/HEV -filter.  
1.2. Intended Use of Investigational Products  
Phase 1:  Not applicable.  Subjects will wear their habitual contact [CONTACT_13276].
Phase 2:  The intended use of the investigative product is for correcting myopia and improving 
visual performance chara cteristics under applic able conditions.  During phase [ADDRESS_905922] c ompr ehensive nonclinical information regarding senofilcon A 
with new UV/HEV -filter, refer to the latest version of the Investigator's Brochure .34
1.4. Summary of Known Risks and Benefits to Hu man Subjects  
Phase 1:
oThe risk / benefits of the subjects’ habitu al lenses are described in their corresponding
patient instruction guide and package insert.
Phase 2:
oBenefits to the subjects include the correc tion of their refractive error with the poten tial
of improved visual performance in HEV environments .  The risks of wearing soft
contact [CONTACT_670608]’s Brochure and
Informed Consent. The material safety testing/lens release criteria was determined
based on the Risk Assessment.
For the most comprehensive risk and benefit information regarding senofilcon A with 
new UV/H EV-filter, refer to the latest version of the Investigator's Brochure .[ADDRESS_905923] lens has been evaluated in two previous objective -based 
studies:  and   In both studie s, psychophysical evaluations were carried out 
on an optical breadboard system using a broadband light source that emulated sunlight in 
spectral content.  These studies demonstrate that benefits of a HEV -filter can be seen when 
tested in an HEV -rich enviro nmen t such as natural sunlight: 
CR-6463, v3.0
Page 29 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
1.  (n=60 cohort): when compared to a similar con tact lens without the new
UV/HEV filter, the Test lens demonstrated statistical superiority in the following
metrics:
o2-point light threshold
oHalo diameter
oStarburst dia mete r
oDisability glare
oDiscomfort glare
oChromatic contrast
2. (n=58 cohort): when compared to a similar contact [CONTACT_670609]/HEV filter (different control lens than ), the Test lens demonstrated
statistical superiority in the foll owin g metrics:
o2-point light threshold
oHalo diameter
oDiscomfort glare
oChroma tic contrast
oPhotostress recovery
To further, many of the metrics noted above provi de a reason to believe that the specific 
hypotheses of this study are obtainable.  Mainly:
1.Impr oved contrast
oIn  and , disability glare ( Figure 8, top) was measured by [CONTACT_670610] a broadband light source needed to obscure a central grating
target.  The results from this st udy demonstrate that subjects can see ahigh
contrast central grating target under HEV -rich conditions such as sunlight better
with an HEV -filter.
oIn  and , heterochromatic contrast ( Figure 8,bottom) was
measured by [CONTACT_670611] a [ADDRESS_905924]
edges while wearing an HEV -filter.
CR-6463, v3.0
Page 30 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
2.Improved acuity
oIn  and , two -point light thresholds were measured by
[CONTACT_249983][INVESTIGATOR_670586] ( Figure 9).
oThis is akin to the separation of Airy discs and thus a resolution task.35The results
demonstrate that subjects can resol ve an image under HEV -rich conditions better
with an H EV-filter.
3.Improved low light vision
In  and , broadband light that emulated sunlight in spectral content was 
used to generate a point source of light.  The halo and starb urst diameters of that light were 
measured using precision calipers ( Figure 10).  The results demonstrate that positive 
dysphotopsia, which is most prevalent in dim illuminat ion, can be improved with an HEV -
filter.36-38
CR-6463, v3.0
Page 31 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Phase 2:
1.Primary Endpoint(s):
xResolution acuity using Landolt C’s under bright light conditions ( a120 cd/m2)
with a broadband glare source. The photopic resolution acuity on arcminute scale
will be converted to logMAR scale for the analysis purpose u singܴܣܯ݃݋݈  =
݃݋݈ଵ଴(݁ݐݑ݊݅݉ܿݎܽ)  ,see Statistical Analysis Section for more informati on(Section
14).
2.Secondary Endpoint (s):
xPhotopic contrast sensitivity under bright light con ditions (a120 cd/m2) with a
broadband glare source. Testing will include [ADDRESS_905925] sensitivity under dim light co nditions ( d3 cd/m2) with a
broadband glare source. Testing will include [ADDRESS_905926] threshold.
2.3. Hypotheses  
Phase 1:
The least -square means (LSM, i.e., adjusted means) of photopic contrast sensitivity and 
mesopic contrast sensitivity at 6 cpd will be estimated with 95% confidence interval separately 
under conditions with glare source and without glare source.  The primary endpoints in phase 
[ADDRESS_905927] the criteria of 0.1 log (per ANSI Z80.12 -2007).  
If the reduction in the estima ted mean due to the glare source is about 0.1 log units, then it can 
be concluded that t he glare light source is effective and the study can move to Phase 2.
Phase 2:
1.Primary Hypothesis:
xThe Test lens will provide improved photopic resolution acuity than the Control
lens under conditions of a br oadband glare source.
2.Secondary Hypotheses
xThe Test lens will provide improved photopic co ntrast sensitivity than the Control
lens under conditions of a broadband glare source.
xThe Test lens will provide improve dmesopic contrast sensitivity under cond itions
of a broadband glare source.
Phase 2: The primary hypothesis must be met to sa tisfy the objective of the study. The 
secondary hypotheses will be evaluated only when the primary hypothesis is met. For both 
primary and secondary endpoints, in addi tion to the statistical testing, the mod el-based point 
estimate of mean difference will be evaluate d against a predetermined clinically meaningful 
margin (0.[ADDRESS_905928] 
sensitivity) .
CR-6463, v3.0
Page 33 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
3.TARGETED STUDY POPULATION
3.1. General Characteri stics 
Subjects must be habitual wearers of silicone  hydrogel contact [CONTACT_486748] a daily wear 
basis.  Subjects can be of any gender, race, and ethnicity that meet the eligi bility criteria.  
Subjects enrolling in phase [ADDRESS_905929] satisfy all of the following criteria to be enrolled in the study:
Inclusion Criteria following Screening
The subject must:
1.Read, understand, and sign the STATEM ENT OF INFORMED CONSENT and
receive a fully executed copy of the form.
2.Appear able and willing to adhere to the instructions set forth in this cli nical protocol.
3.Be between 18 -39 (inclusive) years of age at the time of screening.
4.By [CONTACT_6270] -report, habitually wear spherical sil icone hydrogel soft contact [CONTACT_456100] b oth
eyes in a daily reusable or daily disp osable wear modality (i.e. not extende d wear
modality). Habitual wear is defined as a minimum of [ADDRESS_905930] be between -1.00 D and -6.00 D (inclusive)
in each eye.
Inclusion Criteria following Baseline Evaluation
7.Habitual contact [CONTACT_670595] 20/[ADDRESS_905931] satisfy all of the follow ing criteria to be enrolled in the study:
Inclusion Criteria following Screening
The subject must:
1.Read, understand, and sign the STATEM ENT OF INFORMED CONSENT and
receive a fully executed copy of the form.
2.Appear able and willing to adhere to the instruc tions set forth in this clinical protocol.
3.Be between 18 and 70(inclusive) years of age at the time of screening.
4.By [CONTACT_6270] -report, habitually wear spherical silicone hy drogel soft contact [CONTACT_670612] a daily reusable or daily disposable wear mod ality (i.e. not extended wear
CR-6463, v3.0
Page 34 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
modality). Habitual wear is defined as a minimum of [ADDRESS_905932]’s vertex -corrected distance refraction must be
between -1.00 D and -6.00 D (inclusive) in each eye.
7.The magnitude of the cylindrical component of the subject’s vertex -correct ed distance
refraction must be between 0.00 D and 1.00 D (inclusive) in each eye.
8.The best corrected, monocular, distance visual acuity must be 20/25 or better in each
eye.
3.3. Exclusion Criteria  
3.3.1. Phase 1 Exclusion Criteria  
Potential su bjects who meet any of th e following criteria will be excluded from participating 
in the study: 
Exclusion Criteria following Screening
The subject must not:
1.Be currently pregnant or lactating .
2.Be currently using any ocular medications or have any ocular infection of any type.
3.By [CONTACT_6270] -report, have any ocular or systemic disease, allergies, infection, or use of
medication that might contraindicate or interf ere with contact [CONTACT_13279], or otherwi se
compromise study endpoints, including infect ious disease (e.g., hepatitis, tuberculos is),
contagious immunosuppressive disease (e.g., Human Immunodeficiency Virus [ HIV]),
autoimmune disease (e.g. rheumatoid arthritis, Sjögren’s syndrome), or history of
serious mental illness or seizures. See section 9.1for additional details regarding
excluded systemic medications.
4.Have habitually worn rigid gas perm eable (RGP) lenses, orthokeratology lenses, or
hybrid lenses (e.g. SynergEyes, SoftPerm) within the past [ADDRESS_905933] clinical trial within 30 days
prior to study enrollment.
8.Be an employee (e.g., Investigator, Coordinator, Techni cian) or immediate family
member of an employee (including partner, child, parent, grandparent, grandchild o r
sibling of the employee or their spouse) of the clinical s ite.
Exclusion Criteria following Baseline Evaluation
The subject must not:
9.Have clinic ally significant (grade 3 or higher on the FDA grading scale) slit lamp
findings (e.g., corneal edema, neovasculariz ation or staining, tarsal abnormalities or
bulbar in jection) or other corneal or ocular dise ase or abnormalities that contraindic ate
contact [CONTACT_129803] (including entropi[INVESTIGATOR_2394],
CR-6463, v3.0
Page 35 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
ectropi[INVESTIGATOR_2394], chalazia, recurrent styes, glauco ma, history of recurrent corneal erosions, 
apha kia, moderate or above corneal distortion, herpetic keratitis).
10.Have a histor y of strabi smus or amblyopia.
11.Have fluctuations in vision due to clin ically significant dry eye or other ocular
conditions.
12.Have had any ocular or intraocular surgery (e.g., radi al keratotomy, PRK, LASIK,
iridotomy, retinal laser photocoagulation, etc.).
13.Have signs of a contact [CONTACT_13293] -related corneal inflammatory event (e.g., past peripheral
ulcer or round peripheral scar) .
14.Have a history of eyelid injury, surgery or procedure that resulted in abnormal eyelid
position or movement.
3.3.2. Phase 2 Exclusion Criteria  
Potential s ubjects who meet any of the following crite ria will be excluded from participating 
in the study: 
Exclusion Criteria following Screening
The subject must not:
1.Be curre ntly pregnant or lactating.
2.Be currently using any ocular medications or have any ocular infection of any type.
3.By [CONTACT_6270] -report, have any ocular or systemic disease, allergies, infection, or use of
medication that might contrai ndicate or interfere with con tact lens wear, or otherwise
compromise study endpoints, including infectious disease (e .g., hepatitis, tuberculosis),
contagious immunosuppressive disease (e.g., Human Immunodeficiency Virus [ HIV]),
autoimmune disease (e.g. rheumatoid arthritis, Sjögren’s syndrome), or history of
serious mental illness or seizures. See section 9.1for additional details regarding
excluded systemic medications.
4.Have habitually worn rigid gas perm eable (RGP) lenses, orthokeratolog y lenses, or
hybrid lenses (e.g. SynergEyes, SoftPerm) within the past [ADDRESS_905934] lens or lens care produc t clinical trial within 30 days
prior to study enrollment.
8.Be an employee (e.g., Investi gator, Coordinator, Techn ician) or immediate family
member of an employee (including partner, child, parent, grandparent, grandchild o r
sibling of the employee or their spouse) of the clinical site.
Exclusion Criteria following Baseline Evaluation
The sub ject must not:
9.Have clinically significant (grade 3 or hi gher on the FDA grading scale) slit lamp
findings (e.g., corneal edema, neova scularization or staining, tarsal abnormalities or
bulbar injection) or other corneal or ocular disease or abnormalities t hat contraindicate
contact [CONTACT_129803] (including entropi[INVESTIGATOR_2394],
ectropi[INVESTIGATOR_2394], chalazia, recurrent styes, glaucoma, history of recurr ent corneal erosions,
aphakia, moderate or above corneal distortion, herpetic keratitis) .
CR-6463, v3.0
Page 36 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
10.Have a history of strabismus or amblyopia.
11.Have fluctuations in vision due to clin ically significant dry eye or other ocular
conditi ons.
12.Have had any ocular or intra ocular surgery (e.g., radial keratotomy, PRK, LASIK,
iridotomy, retinal laser photocoagu lation, etc.).
13.Have signs of a contact [CONTACT_13293] -related corneal inflammatory event (e.g., past peripheral
ulcer or round peripheral scar) .
14.Have a history of eyelid injury, surgery or procedure that resulted in abnormal eyelid
position or movement.
3.4. Enrollment S trategy  
Study subjects will be recruited from the Inst itution/clinical site’s subject database and/or 
utilizing Independent Ethics Com mittee (IEC) or Institutional Revi ew Board (IRB) approved 
materials. 
4.STUDY DESIGN AND RATIONALE
4.1. Description of Study Desi gn 
Phase 1: This is a non -randomized, non -masked, non -dispensing study where subjects will 
wear their own contact [CONTACT_670613] 1 hour.  
Phase 2: This is a controlled, randomized, double -masked, contralateral (Test/Control or 
Control/Test), no n-dispensing study where the study lenses will be worn in a daily wear 
modality for approximately [ADDRESS_905935] access to the study lenses at the 
conclusion of their visit.
4.2. Study Design Rationale  
Phase1: T his study phase is to help ensur ethat the intensity of the glare source is efficacious
and satisfies ANSI Z80.[ADDRESS_905936] lense s and be tested 
unilaterally.
Phase 2: This study phase will be executed using a contralateral design.  There are several 
benefits to this choice of design.  First, a contralateral design will allow us to compare 
performance within the same individual, os tensibly with the same baseline light sensitivity by 
[CONTACT_72067].  Second, other subject factors  that can influence visual performanc e, such as iris color and 
absorption of test lights via macular pi[INVESTIGATOR_2517], are better controlled using this design.  Third, in 
psycho physical testing, which is the gold s tandard for many of the visual functions being 
tested, participants make judgments about some event threshold, such as when an image 
disappears.  Participants may have differ ent criteria for threshold events that are in ternally 
consistent within subjects b ut can vary between subjects.  A contralateral design allows the 
investigational lens to be compared within subjects, with consistent criteria for threshold 
events.  Sufficient time will be taken between measures to red uce any potential bias, as follows:
CR-6463, v3.0
Page 37 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
4.3. Enrollment Target and Study Duration  
Phase 1: This phase of the study will enroll up to [ADDRESS_905937] la sting approximately one hour.  
Enroll ment period is approximately one week.
Phase 2: This phase of the study will have an en rollment target of 66subjects, with a goal of
at least 60to complete. The subjects in phase 2 will not in clude the subjects from phase 1.  
The study will be conducte d at 1clinical site (same site as phase 1).  A subject will be 
considered enrolled upon signing of the informed consent form. Approximately 30 subjects 
(+/-5) will be in the age range [ADDRESS_905938] .  Total duration of phase 2 is expected to be 
approximately 8 weeks. 
Total study duration (phase 1 + interim analysis + phase 2) is expected to last about [ADDRESS_905939] locked.
CR-6463, v3.0
Page 38 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
5.TEST ARTICLE ALLO CATION AND MASKING
5.1. Test Article Allocation  
Phase 1:  Not Applicable.  Subjects are wearing thei r habitual contact [CONTACT_13276].
Phase 2: Use of the test articles will be randomized using a lens fitting schedule supplied by 
[CONTACT_15282]. The clini cal site will follow the lens fitting schedule provided and 
will complete enrollment according t o the randomization list and will not pre -select or pre-
assign subjects.
Randomly -permu ted block randomization will be used to avoid bias in the assignment of 
subjects to treatment and to enhance the vali dity of statistical comparisons across treatment 
groups. Subjects, in blocks of two, will be randomi zed to either wear the Test lens in th e left 
eye and the Control lens in the right eye or the Control lens in the left eye and the Test lens in 
the right eye . The order of the light sources ispredetermined : visual performance will be 
assessed under the no broadband light source ( without glare ) condition first and then assessed 
under the broadband light source ( withglare) condition.  The same randomization scheme will 
be used for these two light source s.Under each light source condition, the right eye will always 
be tested first. Subjects wil l be stratified into one of two age groups (18 -39years old and 40 -
70years old ) using a 1:1 allocation ratio. The randomization scheme will be generated using 
the PROC PLAN procedure from Statistical Analysis System (SAS) Software Version 9.4 or 
higher (S AS Institute, Cary, NC).[ADDRESS_905940] occurred prior 
to randomization:
xInformed consent must hav e been obtained .
xThe subject must have met all eligibility criteria .
xThe subject’s scre ening and baseline information must  have been collected .
When releasing test articles for vision testing , the following steps should be followed to 
maintain randomizat ion codes:
1.Investigator or designee (documented on the Delegation Log) will consult the lens
fitting schedule to obtain the test article assignment for that subject prior to dispensing .
2.Investigator or designee will record the subject’s number on the appr opriate line of the
lens fitting schedule.
3.Investigator or designee will pull the approp riate test articles from the study supply.
All test articles that are opened, whether dispensed (placed/fit on eye or dispensed
outside the clinical site) or not, must be recorded on the Test Article Accountability
Log in the “Dispensed” section .
CR-6463, v3.0
Page 39 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Figure 11: Representative image of the primary and secondary packaging for Phase 2.
Primary Packaging Secondary Packaging
6.4. Storage Conditions  
Phase 2: Test articles will be maintained at amb ient temperatures at the clinical site. Test 
articles must be kept under secure conditions .
6.5. Collection and Storage of Samples  
No samples will be collected as part of the study procedures.
When possible for Phase [ADDRESS_905941] article associated with an Adverse Event and/or a 
Product Quality Complaint must be  retained and stored in a glas s vial with moderate solution 
pending directions from the sponsor for potential return to JJVC.
6.6. Accountability of Test Articles  
Phase 2:  JJVC will provide the Invest igator with sufficient quan tities of study articles and 
supplies to complete the investiga tion. The Investigator is asked to retain all lens shipment 
documentation for the test arti cle accountability records. 
Test article smust be kept in a locked storag e cabinet, accessible only to those assigned by [CONTACT_35500]. The Inves tigator may delegate this activity to authorized study site 
personnel listed on the Site Delegation Log. All test articles must be accounted. This includes:
1.What was dispensed for the subject for trial fitting, to wear out  of the office, or issued
for the subject to replace appropriately between visits .
2.What was returned to the Investigator unused , including expi[INVESTIGATOR_35441].
3.The number and reason fo r unplanned replacements .
CR-6463, v3.0
Page 42 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
1.33 Visual Performance 
Testing Without GlareVisual performance testing will be performed 
using the Metropsis system OD and OS in the 
followi ng order.  The eye not being tested 
will be patched.
Without glare OD:
1.Photopic resolution acuity
A. Test distance: 4.0 mB.
Screen luminance approximately 120
cd/m2
C. Ambient luminance must be dark with 
no lights or refl ective surfaces within 
the general field of view of the target.  
EDC to record: Arcminute +/- SD.  
Range 0.[ADDRESS_905942] distance: 1.5 mB. Screen luminance approximately 
120
cd/m2
C.Ambient luminance must be dark with 
no lights or reflective surfaces within 
the general fiel d of view of the target
D. Spatial frequencies 3, 6, 9, 12, [ADDRESS_905943]: contrast threshold 
mean +/- SD for each spatial 
frequency.  Range 0.0000 –100.0000.
E. Rest a minimum of [ADDRESS_905944] distance: 1.5 mB. Screen luminance approximately 3
cd/m2.  This will be achieved by [CONTACT_1299] n
eutral density films over the 
Metropsis monitor.
C.Ambient luminance must be dark with 
no lights or reflective surfaces within 
the general field of vi ew of the target
D.Spatial frequencies 1.5, 3, 6, 9, [ADDRESS_905945]: contr ast threshold 
mean +/- SD for each spatial 
frequency.  Range 0.0000 –100.0000.
CR-6463, v3.0
Page 53 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
1.[ADDRESS_905946].
With glare OD:
1.Photopic resolution acuity
A. Test distance: 4.0 mB.
Screen luminance approximately 120
cd/m2
C.Ambient luminance must be dark with 
no lights or reflective surfaces within 
the general field of view of the target.  
EDC to record: Arcminute +/- SD.  
Range 0.[ADDRESS_905947] distance: 1.5 mB. Screen luminance approxima
tely 120
cd/m2
C.Ambient luminance must be dark with 
no lights or reflective surfaces within 
the general field of view of the target.
D. Spatial frequencies 3, 6, 9, 12, [ADDRESS_905948]: contrast threshold 
mean +/- SD for each spatial 
frequency.  Range 0.0000 –100.0000.
E. Rest a minimum of [ADDRESS_905949] distance: 1.5 mB. Screen luminance approximately 3
cd/m2
C.
Add a 0.[ADDRESS_905950]: contrast threshold 
CR-6463, v3.0
Page 55 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
For discontinued subjects, the Investigator will:
xComplete the current visit (scheduled or unscheduled) .
xComplete the Final Evaluation, in dicating the reason that the subject was discontinued
from the study .
xRecord the spherocylin drical refraction with best corrected distance visual ac uity.
xCollect used test article(s) from the subjec t and discard them, unless otherwise stated
insection 7.2.
xCollect all unused test article(s) from the subject .
xMake arrangements for subject care, if needed, d ue to their study participation
Additional subjects will be enrolled if a subject discontinues from the stu dy prematurely. 
In cases where a subject is lost to follow -up, every possible effort must  be made to contact [CONTACT_312794]/withdrawal. The measures taken to follow
up must be documented including two written att empts and a certified letter (or equivalent) as 
the final attempt. 
9.PRE -STUDY AND CONCOMITANT INTERVENTION/MEDICATION
Concomitant medications will b e documented during screening and updated during the study. 
Disallowed medications for this study include :any ocular medications.
Concomitant therapi[INVESTIGATOR_35443]: see section 9.1.
9.1. Systemic Medications  
Certain systemic medications are known to have a higher likelihood to interfere with contact 
[CONTACT_13279], chiefly by [CONTACT_35509]. 
A summary of disallowed systemic medications is shown in Table 5: Disallowed systemic 
medications . Subjects with a history of taking these medications will be allowed to enroll 
only if:
xThe medications have been taken on a cont inual, routine basis for at least [ADDRESS_905951] lens wear during this time.
Or:
xThe s ubject was taking themedication on a temporary basis and ceased taking that
medication at least 2 weeks prior to signing t he informed consent (this is considered
sufficient time for the medication to have left the body prior to enrollment).
Subjects with a history of taking medications listed inTable 5: Disallowed systemic 
medications on a long-term, routine basis for less than 6 months will not be allowed to 
participate in the study.
CR-6463, v3.0
Page 59 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
The Sponsor will determine when a study will be stopped. The Pri ncipal Investigator always 
has the discretion to initiate stoppi[INVESTIGATOR_670587]’s results are compromised.
JJVC rese rves the right to terminate the study at a ny time for any reason. Additionally, the 
IEC/IRB reserves the right to terminate the study  if an unreasonable risk is determined. The 
study can be terminated by [CONTACT_079] [INVESTIGATOR_670588] l site due to 
specific clinical observatio ns, if in their opi[INVESTIGATOR_1649], after a discu ssion with JJVC, it is determined 
that it would be unwise to continue at the clinical site.
JJVC (and the IEC/IRB and DMC, if applicable) will evaluate all adverse events. If it is 
determined that an adverse event pre sents an unreasonable risk, the investigation, or that part 
of the investigation presenting the risk, will be terminated as soon as possible.
Should the study be terminated (eit her prematurely or as scheduled), th e Investigator will 
notify the IEC/IRB and Regulatory Authority as require d by [CONTACT_35512].
12.PROCEDURE FOR HANDLING PRODUCT QUALITY COMPLAINTS
A Product Quality Complaint (PQC) refers to an y written, electronic, or oral communication 
that alleges deficiencies related to the identi ty, quality, durability, reliabi lity, safety, 
effectiveness or performance of test articles after th ey have been released for clinical trial use.  
Potential complaints may come from a variety of sources including but not limited to subjects, 
clinical res earch associates (CRA), clinical operations managers (COM), medical monitors, 
and site personnel, etc. The following are not considered product quality complaints:
xSubject satisfaction inqui ries reported via “Subje ctive Questionnaires” and “Patient
Reporte d Outcomes (PRO) .”
xClinical test articles that are stored improperly or damaged after receipt at the
investigational site .
xLens replacements that occur due to drops/fall -outs.
xDamage deemed by [CONTACT_670614] l staff to be caused by [CONTACT_670615],
and not indicative of a qual ity deficiency (i.e. tears, rips, etc.), only in situations where
there is no deficiency alleged by [CONTACT_423] .
Within [ADDRESS_905952] be 
recorded in the EDC system, which will trigger an au tomatic email notification to the 
appropriate COM/CRA and Clinical QA representative. In cases where the EDC system in use 
is not configured to send auto matic notifications or when a n EDC system is not used, the 
COM/CRA is r esponsible for notifying Clinica l QA upon discovery that a PQC has occurred.  
Upon receipt of the EDC notification, the COM/CR A will contact [CONTACT_19568]: 
xDate the complaint was received/recorded in the EDC System (Date of Sponsor
Awareness) .
CR-6463, v3.0
Page 62 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
xWho received the complaint .
xStudy number .
xClinical site information (contact [CONTACT_2300], site ID, telephone number) .
xLot number(s) .
xUnique Subject Identifier(s) .
xIndication of who first observed complaint (site person nel or subject) .
xOD/OS indicatio n, along with whether the lens was inserted .
xAny related AE number if applicable .
xDetailed complaint description (scheduled/unscheduled visit, wear time, symptoms,
resolution of symp toms, etc.) .
xEye Care Provider objective ( slit lamp) findings if applicable .
xConfirmation of product availability for return  (and tracking information, if available),
or rationale if product is not available for return 
Once a complaint is received, it will be assesse d by [CONTACT_19569], CRA, or trained site personnel 
to determine if it is an Adverse Event/Seri ous Adverse Event (AE/SAE). If the complaint 
results in an AE/SAE, the COM/CRA, or trained site personnel will follow section13of this 
protocol. If the AE/SAE was potentially the re sult of a product quality related deficienc y, these 
procedures also applies and will be executed in parallel.
In some cases, a PQC form may be gener ated in EDC by [CONTACT_35514]. In this event, the 
PQC forms will be marked “Intentionally Left Bla nk” or “ILB”.  Justification for ILB must be 
documented.
13.ADVERSE EVENTS
13.1. Definitions and Classifications  
Adverse E vent (AE) –An AE is “any untoward medical occurrence, unintended disease or 
injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, users 
or other persons, whether or not related to the i nvestigational medical device. ”
Note:This definition includes events relate d to the investigational medical device or the 
comparator , and to the procedures involved .For users or other persons, this definition is 
restricted to events related to investigational medical device s.1
An AE includes any condition (including a pre -existing condition) that:
1.Was not present pri or to the study, but appeared or reappeared following initiation of
the study .
2.Was present prior to the study but worsened during the study. This would include any
condition resulting from concomitant illnesses, rea ctions to concomitant medications,
or pro gression of disease states .
Note : Pregnancy must be documented as an adverse event and must be reported to the clinical 
monitor and to the Sponsor immediately upon learning of the event.
CR-6463, v3.0
Page 63 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Serious Adverse Event (SAE) –An SAE is any adverse event thatled to any of the following :
xDeath
xSerious deterioration in the health of the subj ect that resulted in any of the following:
xLife-threateni ng illness or injury
xPermanent or persistent impairment of a body structure or a body function
xHospi[INVESTIGATOR_35448] -threatening illness or injury or
permanent impairment to a body structure or a body function.
xChronic disease
xFoetal distress, foetal death or a con genital physical or menta l impairment of birth
defect.
Diagnoses and conditions that are considered Oc ular Serious Adverse Events include, but not 
limited to:
xMicrobial Keratitis (MK)
xIritis (including cells in the anterior chamber)
xPermanen tdecrease in best spectacle corrected visual acuity equi valent to 2 acuity lines
or greater
xCentral Corneal Opacity
xCentral Corneal Neovascularization
xUveitis
xEndophthalmitis
xHypopyon
xHyphemia
xPenetration of Bowman’s Membrane
xPersistent Epi[INVESTIGATOR_35449] –are defined as events that are symptomatic and warrant 
discontinuation (temporary or permanent) of the contact [CONTACT_670616], but 
not limited to the following:
xContact [CONTACT_35516] (CLPU)
xSignificant Infiltrative Events (SIE)
xSuperior Epi[INVESTIGATOR_670589] (SEALs)
xAny Temporary Loss of > [ADDRESS_905953] lens related corneal events -e.g. Epi[INVESTIGATOR_71155] (EKC)
xAsymptomatic Corneal Scar
xAny corneal event which necessitates temporary lens discontinuation > 2 weeks
Non-Significant Adverse Events –are defined as those events that are usually asymptomatic 
and usually do not warrant discontinuation of con tact lens wear but may cause a reduction in 
CR-6463, v3.0
Page 64 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
wear time. However, the Investigator may choose to prescribe treatment as a precautiona ry 
measure .
Diagnoses and conditions that are considered Ocular Non -Significant Adverse Events include, 
but not limited to the following:
xNon-significant Infiltrative Event (N SIE)
xContact [CONTACT_19573][INVESTIGATOR_19534] (CLPC)
xSuperficial Punctate Keratit is(SPK)
xConjunctivitis: Bacterial, Viral, Allergic
xBlepharitis
xMeibomianitis
xContact [CONTACT_35518], which
necessitates temporary lens discontinuatio n <[ADDRESS_905954] (ADE) –An ADE is an “adverse event related to the use of an 
investigational medical device. ”
NOTE 1:This definition includ es adverse events r esulting from insufficient or 
inadequate instructions for use, deployment, imp lantation, installation, or operation, or 
any malfunction of the investigational medical device.
NOTE 2:This definition includes any event resulting from use error or from inten tional 
misuse of the investigational medical device .[ADDRESS_905955] (UADE) –A UADE is a ny serious adverse effect on 
health or safety or any life -threatening problem or death caused by, or asso ciated with, the test 
article, if that effect, problem, or death was not  previously identified in nature, severity, or 
degree of incidence in the investigational p lan, Investigator’s Brochure or protocol, or any 
other unanticipated serious problem associat ed with the test article that relates to the rights, 
safety and welfare of subjects.
13.2. Assessing Adverse Events  
In conjunc tion with the medical monitor, the Investigator will evaluate adverse events to ensure 
the events are categorized correctly. Elements of categorization w ill include:
xSeriousness/Classifications (see definition in section 13.1).
xCausality or Relatedness –i.e. the relationship between the test article , study treatment
or study procedures and the adverse event (not related ,unlikely related ,possibly
related ,orrelated -see definition in section 13.2.1 ).
xAdverse Event Severity –Adverse event severity is used to assess the degree of
intensity of the ad verse event (mild ,moderate ,orsevere -see definition in section 0).
xOutc ome –not recovered or not resolved ,recovering or resolving ,recovered or
resolved with sequelae ,recovered or resolved ,death related to adverse event , or
unknown .
xActions Taken –none,temporarily discontinued ,permanently discontinued , orother .
CR-6463, v3.0
Page 65 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
13.2.1. Causal ity Assessment  
Causality Assessment –A determination of the relationship be tween an adverse event and the 
test article. The test articl e relationship for each a dverse event should be d etermined by [CONTACT_19575]:
xNot Related -Anadverse event that is not related to the use of the test article, study
treatment or study procedures .
xUnlikely Related –An adverse ev ent for which an alternative explanation is more
likely, e.g. concomitant treatment, concomitant disease(s), or the rela tionship of time
suggests that a causal relationship is not likely .
xPossibly Related –An adverse event that might be due to the use of the test article, or
to the study treatment or st udy procedures. An alternative explanation, e.g. concomitant
treatment, concomitant disease(s), is inconc lusive. The relationship in time is
reasonable. Therefore, the causal relationship cannot be excluded .
xRelated –An adverse event that is listed as a p ossible adverse effect (device) or adverse
reaction (drug) and cannot b e reasonably explained by [CONTACT_4867], e.g.
concomitant treatment of concomitant disease(s). The relationship in time is very
suggestive, e.g. it is confirmed by [INVESTIGATOR_5328] -chall enge and re -challenge .
13.2.2. Severity Assessment  
Severity Assessment –A qual itative assessment of the degree of  intensity of an adverse event 
as determined by [CONTACT_19577]/her by [CONTACT_70579] t. The assessment of 
severity is made irrespectiv e of test article, study treatment or study procedure relationship or 
seriousness of the event and should be evaluated according to the following scale:
xMild –Event is noticeable to the subject but is easil y tolerated and does not interfere
with the subje ct’s daily activities .
xModerate –Event is bothersome, possible requiri ng additional therapy, and may
interfere with the subject’s daily activities .
xSevere –Event is intolerable, necessitates additional the rapy or alteration of therapy
and interferes with the subject’s daily activities .
13.3. Documentation and Follow -Up of Adverse  Events  
The recording and documenting of adverse events (ocular and non -ocular) begin when the 
subjects are exposed to the test article, study treatment or study procedure.  Adverse eve nts 
reported before the use of test article, start of study treatment, or study procedures will be 
recorded as medical history. However, if the c ondition deteriorates at any time during the study 
it will be recorded and reported as an AE. Untoward medical events reported after the subject’s 
exit from the study will be recorde d as adverse events at the discretion of the Investigator.
Upon finding an adverse event, the Principal Investigator [INVESTIGATOR_653789].  
Complete descriptions of all ad verse events must be availa ble in the subject record. All 
Adverse Events including local and systemic reactions not meeting the criteria for “serious 
adverse events” shall be captured o n the appropriate case report form or electronic data system. 
CR-6463, v3.0
Page 66 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
All adver se events occurring while the subject is enrolled in the study must be documented 
appropriately regardless of relationship.  
It is the Investigator’s responsibility to maintain documentation of each reported adverse event. 
All adverse events will be foll owed in accordance with applicable licensing requirements. Such 
documentation will include the following:
xAdverse event (diagnosis not s ymptom) .
xDrawings or photographs ( where appropriate) that detail the finding (e.g., size,
location, and depth, etc.) .
xDate the clinical site was notified .
xDate and time of onset .
xDate and time of resolution .
xAdverse event classification, severity, and rela tionship to test articles, as applicable .
xTreatment regimen instituted (where appropriate) , including concomitant medica tions
prescribed, in accordance with applicable licensing requirements .
xAny referral to another health care provider if needed .
xOutcome, ocular damage (i f any) .
xLikely etiology .
xBest corrected visual acuity at the discovery of the event and upon conclusion of the
event , if the AE is related to the visual system .
Upon discovery of an AE that is deemed ‘possibly related ’or ‘related ’to the test article or 
study procedures (whether related to the visual system or not), a nAE review form 
must be co mpleted .Additional dated and initialed entries should be made atfollow -up 
evaluations .Separate forms must be completed for each eye i f the AE is bilateral. 
In addition, if an infiltrate(s) is present, he/she will complete the Corneal Infiltrate Assess ment
eCRF. Where necessary, a culture of the corne al lesion will be collected to determin e if the 
infection is microbial in nature. If c ultures are collected, the da te of culture collection and 
laboratory utilized will be recorded. 
Changes in the severit y of an AE shall be documented to  allow an assessment of the duration 
of the event at eac h level of intensity to be performed. Adverse e vents characterized as 
intermittent require documentation of the onset and duration of each epi[INVESTIGATOR_1865]. Changes in the 
assessment of relationship to the Test Article shall also be clearly documented.
Subjects wh o present with an adverse event shall be follow ed by [CONTACT_737], within 
licensure, until all signs and symptoms have returned to pre -treatment status, stabilized , or 
been satisfactorily resolved. If further treatment beyond licensure is required, the patient will 
be referred to the appropriate he alth care provider. The Investigator will use his/her clinical 
judgment as to whether a subject reporting with an advers e event will continue in the study. If 
a subject is discontinued from the study, it will be the responsibility of the Investigator to 
record the reason for discontinuation. The Investig ator will also document the adverse event 
appropriately and complete th e Adverse Event eCRF. Any subjects with ongoing adverse 
events related to the test articl e, study treatment or study procedures, as of t he final study visit 
CR-6463, v3.0
Page 67 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
date, should be followed to resolution of the adverse event or until referral to an appropriate 
health care provider, as recommended by [CONTACT_737]. Non -ocular adverse events that are
not related to the test article, study treatme nt, or study procedures may be recorded as 
“ongoing” without further follow -up.
13.4. Reporting Adverse Events 
The Investigat or will notify the Sponsor of an adverse event by e -mail, facsimile, or telephone 
as soon as possible and no later than 24 hours from di scovery for any serious /significant 
adverse events, and 2 days from discovery for any non -significant adverse event. In addition, 
a written report will be submitted by [CONTACT_3433] e Principal Investigator [INVESTIGATOR_35451]/IR B according to 
their requirements ( section 13.4.2 ). The report will comment whether the adverse event was 
considered to be related to the test arti cle, study treatment or study procedures.
13.4.1. Reporting Adverse Events to Sponsor  
Serious/Significant Adverse Event s
The Investigator will inform the sponsor of all serious/significant adverse events occurring 
during the study period a s soon as possible by e -mail or telephone, but no later than 24 hours 
following discovery of the event. The Investigator is obligated to pursue and obtain 
information requested by [CONTACT_35519]. All 
subjec ts experie ncing a serious/significant adverse even t must be followed up and all outcomes 
must be reported.
When medically necessary, th e Investigator may break the randomization code to determine 
the identity of the treatment that the subject received. Th e Sponsor and study monitor should 
be notified prior to unmasking the test articles.
In the event of a serious/significant adverse even t, the Investigator must:
xNotify the Sponsor immediately .
xObtain and maintain in the subject’s records all pertinent med ical infor mation and
medical judgment for colleagues who a ssisted in the treatment and follow -up of the
subject .
xProvide the Sponsor wit h a complete case history which includes a statement as to
whether the event was or was not related to the use of the te st article .
xNotify the IEC/IRB as required by [CONTACT_6179]/IRB reporting procedure according to
national regulations .
Unanticipated (Serious ) Adverse Device Effect (UADE)
In the event of an Unanticipated (Seri ous) Adverse Device Effect (UADE), the Investigator
will submit a report of the UADE to the Sponsor and IEC/IRB as soon as possible, but no later 
than [ADDRESS_905956] report the results of the 
evaluation to FDA, the IEC/IRB and participating Investigators within [ADDRESS_905957].
CR-6463, v3.0
Page 68 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Non-Serious Adverse Events
Allnon-serious a dverse events, including non -serious adverse device effects, will be reported 
to the sponsor by [CONTACT_35521] 2 days fr om discovery.
13.4.2. Reporting Adverse Events to the Responsible IEC/IRB and Health Authorities  
Adverse events tha t meet the IE C/IRB requirements for reporting must be reported within the 
IEC/IRB’s written guidelines. Each clinical site will refer to and follow a ny guidelines set forth 
by [CONTACT_19581]/IRB. Each clinical si te will refer to and follow any guideli nes set forth
by [CONTACT_19582].
The Sponsor will report applicable Adverse Events to the local health authorities accordi ng the 
written guidelines, incl uding reporting timelines. 
13.5. Event of Special Interest  
None .
13.6. Reporting of Pregnancy  
Subjec ts reporting pregnancy (by [CONTACT_6270] -report) during the study will be discontinued after the 
event is recorded as an Adverse Event. Once disc ontinued, pregnant participants and their 
fetuses will not be monitored for study related p urposes. Pregnant participant s are not 
discontinued from contact [CONTACT_126124] d studies for safety concerns, but due to 
general concerns relating to pregna ncy and contact [CONTACT_19584]. Specifically, pregnant women are 
discontinued due to fluctuations in refractive error and/or v isual acuity that occur secondary to 
systemic hormonal changes, and not due to unforeseen health risks to the mother or fetus.
14.STATISTIC AL METHODS
14.1. General Considerations  
Statistical Analysis will be undertaken by [CONTACT_670617] s ponsor. A 
general description of the statistical methods to be implemented in this clinical trial is outlined 
below.
All data summarie s and statistical analyses will be performed using the SAS software Version 
9.4 or higher (SAS Institute, Cary, NC) .39Throughout the analysis of data, the results for each 
subject/eye will be used when available for summarization and statistical analy sis. 
Unscheduled visits will be summarized separately and will be excluded from the statistical 
analysis.
Summary table s (descriptive statistics and/or frequency tab les) will be provided for all baseline 
variables, efficacy variables and safety variables as appropriate. Continuous variables will be 
summarized with de scriptive statistics (n, mean, standard deviation (SD), m edian, minimum 
and maximum). Frequency count an d percentage of subjects or eyes within each category will 
be provided for categorical da ta.
CR-6463, v3.0
Page 69 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
14.5. Primary Analys es 
Phase I (interim analysis) :
For photopic and mesopic contrast sensitivity, thelogarithm of contrast sensitivity will be 
calculated as ܵܥ݃݋݈= ݃݋݈ଵ଴(1/(ݐݏܽݎݐ݊݋ܿ  ݐℎݏ݁ݎℎ݈݀݋/100 ))and the logCS will be used for 
the analysis purpose. Note that ݐݏܽݎݐ݊݋ܿ  ݐℎݏ݁ݎℎ݈݀݋ is reported in percentage (%) in the 
Electronic Data Capture system. Photopic and mesopic lo gCS will be analyzed separately 
using linear mixed effects models with a normal  distribution. The dependent variable will be 
the logCS and light source condition (i.e ., without glare and with glare) wil l be the fixed effect 
in both models. A subject -specif ic random intercept will be in cluded to account for repeated 
measurement on the same individuals. The least -square means (LSM, i.e., adjusted means) of 
photopic and mesopic logCS at 6 cpd will be estima ted with 95% confidence interval under 
each light sour ce condition. The reduction in the estimated means due to the glare source will 
be compared against the criteria of 0.1 log. If the reduction in the estimated mean due to the 
glare source is about 0.1 l og units, it can be concluded that the glare light sou rce is verified 
and the study can move to Phase 2.  
Phase 2:
Superiority testing with respect to the primary endpoint in phase 2 will be assessed on the 
Intent -to-Treat (ITT) population.
Photopic Resolution Acuity using Landolt C’s with a Glare Source
The photopic resolution acuity using Landolt C’s (converted to logMAR unit using 
ܴܣܯ݃݋݈  = ݃݋݈ଵ଴(݁ݐݑ݊݅݉ܿݎܽ) )will be analyzed under bright light conditions with a 
broadband light source (glare) using a linear mixed model with a normal distribution. Lens 
type, dominant eye, and the interaction of lens type by [CONTACT_670618] a covariate. The covariance of  residuals between eyes within 
the same subject (R -side) will be modeled using U nstructured (UN) covariance structure. If 
the model does not converge, then a compound Sy mmetry (CS) covariance structure will be 
considered. The Kenward and Roger method (Kenward a nd Roger, 1997) will be used for the 
denominator degrees of freedom.
Hypo thesis Testing
The null and alternative hypotheses for testing superiority of the Test lens relative to the 
Control lens with respect to photopic resolution acuity with a glare source are as follows: 
ܪ଴:ߤ்− ߤ஼≥0
ܪ஺:ߤ்− ߤ஼ <0
Where, ߤ்represents the mean photopic resolution acuity (logMAR) for the Test lens and ߤ௖
represents the mean photopic resolution acuity (logMAR) for the Control lens. Statistical 
superiority will be declared if the upper bound of the adjust ed2-sided 95% confidence interval 
of the mean difference (Test –Control )is lessthan 0. A model -based point estimate of mean 
difference being -0.05 logMAR or more (≤-0.05 logMAR) will be considered clinically 
meaningful .
CR-6463, v3.0
Page 73 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
14.6. Secondary Analyses   
Superiority testing with respect to the secondary endpoint sin phase 2 will be assessed on the 
Intent -to-Treat (ITT) population.
Photopic Contrast Sensitivity with aGlare Source
For photopic and mesopic contrast sensitivity, first the logarithm of contrast sensit ivity will be 
calculated as ܵܥ݃݋݈= ݃݋݈ଵ଴(1/(ݐݏܽݎݐ݊݋ܿ  ݐℎݏ݁ݎℎ݈݀݋/100 )), and then the area under the log
contrast sensitivity function (AUL CSF) will be calculated using logCS and the log (base 10) 
of each spatial frequency based on thetrapezoidal rule per eye per subject for the analysis 
purpose.[ADDRESS_905958] sensitivity will  be analyzed under bright light conditions 
with a broadband light source (glare) using a linear mixed model with a normal distribution. 
Lens type, dominant eye, and the int eraction of lens type by [CONTACT_670619] a covariate. The covariance of residuals between eyes 
within the same subject (R -side) will be modeled using Unstructured (UN) covariance 
structure. If the mode l does not converge, then a compound Symmetry (CS) covariance 
structure will be considered. The Kenward and Roger method will  be used for the denominator 
degrees of freedom.[ADDRESS_905959] sensitivity with a broadband light 
source are presented below:
ܪ଴:ߤ்− ߤ஼≤0
ܪ஺:ߤ்− ߤ஼ >0
Where, ߤ்represents the mean AULCSF for the Test lens and ߤ௖represents the mean AULCSF
for the Control lens. S tatistical s uperiority will be declar ed if the lower bound of the 2-sided
95% confidence interval of the mean difference (Test –Control) is larger than 0. A model -
based point estimate of the mean di fference being 0.06 log or more ( ≥0.06 log) will be 
considered clinically meaningful .[ADDRESS_905960] sensitivit y testing under dim light conditions with a 
broadband light source (glare) will be analyzed, te sted, and interpreted in the same manner as 
the analysis of the AULCSF for photo pic cont rast sensitivity.
14.7. Other Exploratory Analys is  
Other exploratory analysis may  be conducted at the discre tion of the study responsible 
clinician.
CR-6463, v3.0
Page 74 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
14.8. Interim Analysis  
This is a two -phase study and approximately 24 subjec ts will be enrolled in phase 1 wi th a 
target of 20 to complete. An interim analysis w ill be performed after all subjects completed 
phase 1 on the primary endpoints (see Section 14.5 for the details of the planned interim 
analysis). Other endpoints in phase 1 may be descriptive summarized. The int erim analysis on 
the primary endpoints in phase 1 will be used to verify the glare light source. If the glare light 
source is found effective (e.g., the reduction in the estimated mean of contrast sensitivity due 
to the glare source is about 0.1 lo g units ), the study can move to Phase 2. If the glare source 
has no effect, or obliterates the target, then ph ase [ADDRESS_905961] KEEPI[INVESTIGATOR_1645]/ARCHIVING
15.1. Electronic Case Report Form/Data Collection  
The Vision Assessments (photopic and mesopic contrast sensitivity, photopic resolution 
acuity ) will be collected using the Ca mbridge Research Systems Metrop sis system. This data 
will be generated as PDF files. The data from the Metropsis and all other study data will be 
captured on electronic case report forms (eCRFs) using the Bio clinica EDC system. An
authorized data originator will enter study da ta into the eCRFs using the EDC system. Data 
collected on equipment that is not ca ptured in EDC wil l be formatted to the specification of 
the JJVC database manager and sent to JJVC for analysis. 
The source data from the Metropsis will be tran sferred by [CONTACT_152857] f to JJVC in regular 
intervals to be reviewed by [CONTACT_19599]. The data will b e uploaded to a c loud-based system, such as 
MBox, by [CONTACT_7893]. The uploaded data will be  remotely source verified by [CONTACT_670620]. The Metropsis source data will be 
stored at the site in accordance with S ection 19of this protocol. The Metropsis source data 
stored at the site will be stored confidentially  and will only be accessible by [CONTACT_670621]. 
The source data stored at the site may be sto red on an external protected dr ive or a protected 
shared drive. 
External datasources for this study include: Not Applicabl e
CR-6463, v3.0
Page 75 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
The clinical data will be recorded on de dicated eCRFs specifically designed to match the study 
procedures for each visit. Only specifically delegated staff ca n enter data on a CRF.  Once 
completed, the eCRFs will be reviewed for accuracy and completeness and signed by [CONTACT_3786]. The sponsor or sponsor’s representatives will b e authorized to gain access to the 
subject record ation for the purposes of monit oring and auditing the study. 
Edit checks, electronic queries, and audit trails ar e built into the system to ensure accurate and 
complete data collection. Data will be transm itted from the clinical site to a secure central 
database as forms are completed or updated, ensuring information accuracy, security, and 
confidentiality. After the final database lock, the Investigator will be provided with Individual 
Patient Profiles (IP P) including the full audit trail on electronic m edia in PDF format for all of 
the study data. The IPP must be retained in the study files as a certified copy of the source data 
for the study. 
The content and structure of the eCRFs are compliant with ISO [ZIP_CODE]:[ADDRESS_905962] should be available fo r the following: 
xsubject identification
xeligibility
xstudy identification
xstudy discussion
xprovision of and date of informed consent
xvisit dates
xresults of safety and efficacy parameters as required by [CONTACT_670622] o f all adverse events
xfollow -upof adverse events
xmedical history and concomitant medication
xtest article receipt/dispensing/return records
xdate of study completion
xreason for early discontinuation o f test article or withdrawal from the study, if
applicable
The subject record is the eCR F or an external record. The author of an entry in the subject 
record must be identifiable. The first point of entry is considered to be the source record.
Adverse event notes must be reviewed and initialed by [CONTACT_148606].
15.3. Trial Registration on Clini calTrials.gov  
This study will be registered on ClinicalTrials.gov by [CONTACT_1034].
CR-6463, v3.0
Page 76 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
16.DATA MANAGEMENT
16.1. Access to Source Data/Document  
The Investigator/Institution will permit trial -related monitoring, audits, IEC/IRB review and 
regulatory inspection(s) by [CONTACT_670623]/documents. Should the 
clinical site be contact[CONTACT_35527]/IRB or regulatory authority , JJVC must be 
contact[CONTACT_19592] [ADDRESS_905963] and therefore may disclose it as required 
to other clinical investigators and t o regulatory agencies. In order to allow the use of the 
information derived from this clinical study, the Investigator understands that he/she has an 
obligation to p rovide complete test results and all data developed during this study to the 
Sponsor.
16.3. Data Quality Assurance  
Steps will be taken to ensure the accuracy and reliability of data, include the selection of 
qualified investigators and appropriate clinical sites and review of protocol procedures with 
the Principal Investigator. The Principal Investiga tor, in turn, must ensure that all Sub -
Investigators and clinical site personnel ar e familiar with the protocol and all study -specific 
procedures and have appropriat e knowledge of the study article.
Training on case report form completion will be provided to clinical site personnel bef ore the 
start of the study. The Sponsor will review case report forms for accuracy and completeness 
remotely during the conduct of the study, during monitoring visits , and after transmission to 
data management. Any data discr epancies will be resolved with the Investigator or designee, 
as appropriate.
Quality Assurance representatives from JJVC may visit clinical sites to review data pro duced 
during the study and to access compliance w ith applicable regulations pertaining to t he conduct 
of clinical trials. The clinical sites will provide direct access to study -related source 
data/documents and reports for the purpose of monitoring and aud iting by [CONTACT_71182].
16.4. Data Monitoring Commi ttee (DMC)  
Not applicable
CR-6463, v3.0
Page 77 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
17.CLINI CAL MONITORING
The study monitors will maintain close contact [CONTACT_35530] [INVESTIGATOR_35453]’s designated clinic al site personnel. The monitor’s responsibilities will include:
xEnsuring that the investiga tion is being conducted accordi ng to the protocol, any
subsequent versions , and regulatory requirements are maintained .
xEnsuring the rights and wellbeing of subjects are protected .
xEnsuring adequate resources, including facilities, laboratories, equipment, and
qualified clinical site pe rsonnel .
xEnsuring that protocol deviations are documen ted with corrective action plans, as
applicable .
xEnsuring that the clinical site has sufficient test article and supplies .
xClarifying questions regarding the study .
xResolv ing study issues or problems th at may arise .
xReviewing of study records and source documentation veri fication in accordance with
the monitoring plan .
18.ETHICAL AND REG ULATORY ASPECTS
18.1. Study -Specific Design Considerations  
Potential subjects will be fully infor med of the risks and requiremen ts of the study and, during 
the study, subjects will be given any new informati on that may affect their decision to continue 
participation. Subjects will be told that their consent to par ticipate in the study is voluntary and
may be withdrawn at any time w ith no reason given and without pe nalty or loss of benefits to 
which they would otherwise be entitled. Subjects will only be enrolled if the subject is fully
able to understand the risks, benefits, and potential adverse event s of the study and provide 
their consent voluntarily.
18.2. Investigator Responsibility  
The Principal Investigator [INVESTIGATOR_71157], the investigational plan, section 4 of th e ICH E6 (R2)
guidelines on Good Clinical Practice (GCP) ,2and applicable regulatory requirements. GCP is 
an international ethical and scientific  quality standard for designing, co nducting, recording, 
and reporting studies that involve the par ticipation of human subjects. Compliance with this 
standard provides public assurance that the rights, safety, and well -being of study subjects are 
protected, consistent with the principles of the Declaration of Helsinki 64th WMA General 
Assembly [ADDRESS_905964] maintain 
clinical study files in accordance with sectio n 8 of the ICH E6 (R2) guidelines on Good Clinical 
Practice (GCP ),2and applicable regulatory requirements.
18.3. Independent Ethics Committee or Inst itutional Review Board (IEC/IRB)  
Before the start of the study, the Investigator (o r Sponsor when applicable) will provide the 
IEC/IRB with current and complete co pi[INVESTIGATOR_23747] (where applicable):
xFinal protocol .
CR-6463, v3.0
Page 78 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
xSponsor -approved informed consent form (and any other written materials to be
provided to the subjects)
xInvestigator’s Brochure (or equivalent information) .
xSponsor-approved subject recrui tment materials .
xInformation on compensation for study -related injuries or payment to subjects for
participation in the study .
xInvestigator’s curriculum vitae, clinical licenses, or equivalent information (unless not
required, a s documented by [CONTACT_8134]/IRB) .
xInformation regarding funding, name [CONTACT_17008] S ponsor, institutional affiliations, other
potential conflicts of interest, and incentiv es for subjects .
xAny other documents that the IEC/IRB requests to fulfill its obligation .
This stu dy will be undertaken only a fter IEC/IRB has given full approval of the final protocol,
the informed consent form, applicable recruiting materials, and subje ct compensation 
programs, and the Sponsor has received a copy of this approval. This approval lette r must be 
dated and must cle arly identify the documents being approved.
During the study, the Investigator (or Sponsor when applicable) will send the follow ing
documents to the IEC/IRB for their review and approval, where appropriate:
xProtocol revisions
xRevision(s) to informed conse nt form and any other written  materials to be provided to
subjects
xIf applicable, new or revised subject recruitment materials ap proved by [CONTACT_35531] -related injuries or payment to subjects f or
participation in the stud y
xInvestigator’s Brochure revisions
xSummaries of the status of the study (at lea st annually or at intervals stipulated in
guidel ines of the IEC/IRB)
xReports of adverse events that are serious, unanticipated, and associated with the test
articles, accordin g to the IRB’s requirements
xNew information that may adversely affect th e safety of the subj ects or the conduct of
the study
xMajo r protocol deviations as required by [CONTACT_6179]/IRB
xReport of deaths of subjects under the Investigator's care
xNotification if a n ew Investigator is responsible f or the study at the clinical site
xAny other requirements of the IEC/IRB
For protocol revisions that increase subject risk, the revisions and applicable informed consent 
form revisions must be submitted promptly to the IEC/I RB for review and approval before 
implementation of the change(s).
At least once a year, the IEC/IRB will review and reapprove t his clinical study. This request 
should be documented in writing.
CR-6463, v3.0
Page 79 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
At the end of the study, the Investigator (or Sponsor where required) will notify the IEC/IRB 
about the study completion. Documentation of this not ification must be retained at the clinical
site and a copy provided to the CRO or Sponsor as applicable.
18.4. Informed Consen t 
Each subject or their representative, must give written consent according to local requirements 
after the nature of the study has been fully explained. The consent form must be signed before 
performance of any study -related activity. The consent form tha t is used must be approved by 
[CONTACT_670624] d by [CONTACT_90818]/IRB. The infor med consent is in accordance with 
principles that originated in the Declaration of Helsinki,3current ICH GCP2and ISO 
[ZIP_CODE]:20201guidelines, applicable regulatory requi rements, and Sponsor Policy.
Before entry into t he study, the Investigator or an authorized member of the clinical site 
personnel must explain to potential subject the aims, met hods, reasonably anticipated benefits, 
and potential hazards of the study, and any discomfort it may entail. Subjects will be i nformed 
that their participation is voluntary and that th ey may withdraw consent to participate at any 
time. 
The subject will b e given sufficient time to read the i nformed consent form and the opportunity 
to ask questions. After this explanation and befo re entry into the study, consent should be 
appropriately recorded by [CONTACT_19720]'s dated signature. After having obtaine d the 
consent, a copy of the informed consent form must be given to the subjec t.
18.5. Privacy of Personal Data  
The collection, proce ssing and disclosure of personal da ta and medical information related to 
the Study Subject, and personal data related to Principa l Investigator and any clinical site 
personnel (e.g., name, clinic address and phone number, curriculum vitae) is subject to 
compliance with the Health Information Portabilit y and Accountability Act (HIPAA) and other 
applicable personal data protection and security laws and regulations.45,46Appropr iate 
measures will be employed to safeguard thes e data, to maintain the confidentiality of the 
person’s related health and medica l information, to properly inform the concerned persons 
about the collection a nd processing of their personal data, to grant th em reasonable access to 
their personal data and to prevent access by [CONTACT_35532].
All information obtained during the c ourse of the investigation will be  regarded as confidential. 
All personal data gathered in this trial will be treated in strict est confidence by [CONTACT_4718], 
monitors, Sponsor’s personnel and IEC/IRB. No data will be disclosed to any third party 
without the express permission of the subject c oncerned, with the exception of Sponsor
personnel (monitor, auditor), IEC/IRB and regula tory organizations in the context of their 
investigation related activities that, as part  of the investigation will have access t o the CRFs 
and subject records.
The collection and processing of personal dat a from subjects enrolled in this study will be 
limited to those data that are necessary to invest igate the efficacy, safety, quality, and utility of 
the investigational product(s ) used in this study.
CR-6463, v3.0
Page 80 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
These data must be collected  and processed with adequat e precautions to ensure confidentiality 
and compli ance with applicable data privacy protection laws and regulations.
The Sponsor ensures that the personal data will be:
xprocessed fairly and lawfully .
xcollected for specified, explicit, and legitimate purposes and not further processed in a
way incompatibl e with these purposes .
xadequate, relevant, and not excessive in relation to said purposes .
xaccurate and, where necessary, kept cu rrent .
Explicit consent for the processing of personal data will be obtained from the participating 
subject before collection of data. Such consent should also a ddress the transfer of the data to 
other entities and to other countries.
The subject has the right to request through the Investigator access to his pers onal data and the 
right to request rectif ication of any data that are not correct or complete. Reasonable steps 
should be taken to respond to such a request, taking into consideration the nature of the request, 
the conditions of the study, and the applicab le laws and regulations.
Appropriate technical and organizational measures to protect the personal data against 
unauthorized disclosures or access, accident al or unlawful destruction, or acciden tal loss or 
alteration must be put in place. Sponsor personne l whose responsibilities require access to 
personal data agree to keep the identity of study subjects confidential .
19.STUDY RECORD RETENTION
In compliance with the ICH GCP guidelines ,2the Investigator/Institution will maintain all 
CRFs and all subject records that support the d ata collected from each su bject, as well as all 
study documents as specified in ICH GCP2and all study documents as specified by [CONTACT_12926](s). The Investigator/Institution will take m easures to prevent 
accidental or premature destruction of these d ocuments.
Essential documents must be retained until at least two ( 2)years after the last approval of a 
marketing application in an ICH region and until there are no pending or contemplated  
marketing applications in an ICH  region or until at least two (2 )years have elapsed since the 
formal discontinuation of clinical developmen t of the investigational product. These 
documents will be retained for a longer period if required by [CONTACT_76542] e regulatory 
requirements or inst ructed by [CONTACT_1034]. It is the responsibility of the Sponsor to inform the 
Investigator/Institution as to when these documents no longer need to be retained.
If the responsible Investigator retires, relocates, or for oth er reasons withdraws from the 
responsibility of keepi[INVESTIGATOR_8090], custody must be transferred to a person who will 
accept the responsibility. The Sponsor must be not ified in writing of th e name [CONTACT_19619].  Under no circumstan ce shall the Investigator relocat e or dispose of any 
study docume nts before having obtained written approval from the Sponsor.
CR-6463, v3.0
Page 81 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
If it becomes necessary for the Sponsor or the appropriate regulatory authority to review any 
documentation relating to this stud y, the Investigator must permit access to such reports.
If the I nvestigator has a question regarding retenti on of study records, he/she should contact 
[CONTACT_19599].
20.FINANCIAL CONSIDERATIONS
Remuneration for study services and e xpenses will be set forth in detail in the Clinical Research 
Agreeme nt. The Research Agreement will b e signed by [CONTACT_079] [INVESTIGATOR_1238] a JJVC 
management representative prior to study initiation.
JJVC reserves the right to withhold remunera tion for costs associated with protocol vio lations 
such as:
xContinuing an ineligible subject in the study .
xScheduling a study visit outside the subject’s acceptable visit range .
JJVC reserves the right to withhold final remuneration until all study related activities have 
been completed, such as:
xQuery resolution .
xCase Report Form signature .
xCompletion of any f ollow -up action items .
21.PUBLICATION
This is a single site study.  Th e participating institution and Principal Investigators for this 
study agree that, should the study results be published, th e first publicati on of the results of 
this study shall be made in conjunction with the presentation of a joint publication of the study 
results with the investigators contributing data, analyses and comments.
22.REFERENCES
1. ISO [ZIP_CODE]:20 20: Clinical Investigation of Medical Devices for Human Subjects —
Good Clinical Practice. Available at https://www.iso.org/standard/[ZIP_CODE].html
2. International Conference on Harmonization Good Clinic al Practice E6 (ICH -GCP).
Available at http://www.ich.org/products/guid elines/efficacy/article/efficacy -
guidelines.html
3. Declaration of Helsinki -Ethical p rinciples for Medical Research Involving Human
Subjects. Availabl e at https://www.wma.net/policies -post/wma -decla ration -of-
helsinki -ethical -principles -for-medical -research -involv ing-human -subjects/
4. [LOCATION_002] (US) Code of Federa l Regulations (CFR). . Available at
https://ww w.gpo.gov/fdsys/browse/collectionCfr .action?coll ectionCode=CFR
5. Ouyang X, Yang J, Hong Z, Wu Y, Xie Y, Wang G. Mechanisms of blue light -induced
eye hazard and protective measures: a review. Biomedicine & Pharmacotherapy.
2020;130:110577.
CR-6463, v3.0
Page 82 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
6. BOETTNER EA , WOLTER JR. Transmission of the Ocular Media. Investigative
Opht halmology & Visual Science. 1962;1(6):776 -783.
7. Roberts JE. Ocular phototoxicity. Journal of Photochemistry and Photobiology B:
Biology. 2001;64(2 -3):[ADDRESS_905965] age -related macular
degeneration ?Progress in Retinal and Eye Research. 2004;23(5):523 -531.
9. Pawlak A, Ró żanowska M, Zareba M, Lamb LE, Simon JD, Sarna T. Action spectra
for the photoconsumption of oxygen by h uman ocular lipofuscin and lipofuscin
extracts. Archives of Biochemistry and Biophysics. 2002;403(1):[ADDRESS_905966] ER. A New Approach to Measuring the Action
Spectrum for Singlet Oxygen Production by [CONTACT_670625].
Photoch emistry and Photobiology. 2005;81(6):1347.
11. Buch J, Hammond B. Photobiomodulation of the Visual System and Human Health.
International journal of molecular sciences. 2020;21(21):8020.
12. O'Hagan JB, Khazova M, Price LLA. Low -energy light bu lbs, compute rs, tablets and
the blue light hazard. Eye (Lond). 2016;30(2):230 -233.
13. Van Den Berg TJTP, Ijspeert JK. Light scattering i n donor lenses. Vision Research.
1995;35(1):169 -177.
14. Thaung J, Sjöstrand J. Integrated li ght scattering as a function of wavele ngth in donor
lenses. Journal of the Optical Society of America A. 2002;19(1):152.
15. Bornman JF, Reuber S, Cen YP, Weissenb öck G. Ultraviolet radiation as a stress factor
and the r ole of protective pi[INVESTIGATOR_165639]. In: Lumsden P, ed. Plants and UV -B: Responses
to Environmental Change. Cambridge: Cambridge University Press; 1997:157 -168.
16. Collini E. Carotenoids in Photosynthesis: T he Revenge of the “Accessory” Pi[INVESTIGATOR_165639].
Chem. 2019;5(3):4 94-495.
17. Jones P, Lucock M, Veysey M, Beckett E. The Vitamin D ⁻Folate H ypothesis as an
Evolutionary Model for Skin Pi[INVESTIGATOR_371]:  An Update and Integration of Current
Ideas. Nutrients. 2018;10(5):5 54.
18. Muntz WRA. On yellow len ses in mesopelagic animal s.Journal of the Marine
Biological Association of the [LOCATION_008]. 1976;56(4):963 -976.
19. Somiya H. Functional significance of the ye llow lens in the eyes of Argyropelecus
affinis. Marine Biolog y. 1976;34(2):93 -99.
20. Walls GL, Judd HD. THE INTRA -OCU LAR COLOUR -FILTERS OF
VERTEBRATES. British Journal of Ophthalmology. 1933; 17(11):641 -675.
21. Hammond BR, Sreenivasan V, Suryakumar R. The Effects of Blue Light -Filtering
Intraocular Lenses on the Pr otection and Function of the Visual System. Clin
Ophthalm ol.2019;13:2427 -2438.
22. Johnson TP, Sejvar J, Nutman TB, Nath A. The Pa thogenesis of Nodding Syndrome.
Annu Rev Pathol. 2020;15:395 -417.
23. Dutta Gupta S, Agarwal A. Artificial Lighting System fo r Plant Growth and
Development: Chronological Advancement , Working Principles, and Comparative
Assessment. In. Light Emitting Diode s for Agriculture : Springer Singapore; 2017:[ADDRESS_905967] ivers???
Recognition Performance Under Day or Night Condi tions. Optometry and Vision
Science. 2005;82(8):698 -705.
CR-6463, v3.0
Page 83 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
25. Owsley C, Slo ane ME. Contrast sensitivity, acuity, and the perception of 'real -world'
targets. British Journal of Ophthalmology. 1987;71(1 0):791 -796.
26. Tuchinda C, Srivannaboon S, Lim HW. Photo protection by [CONTACT_670626], automobile
glass, and sunglasses. Journal of t he American Academy of Dermatology.
2006;54(5):[ADDRESS_905968] sensitivity fu nction (CSF) as a
measure of disability glare. Invest Oph thalmol Vis Sci. 1986;27(7):1131 -1136.
28. Nankivil D, Hammond R.  Technic al Document ( ) Light Safety for
CSF with Glare and VA with Glare Stimuli at the University of Georgia . August 12,
[ADDRESS_905969] asty. Br J Ophthalmol. 2004;88(5):653 -657.
30. Leon AC, Davis LL, Kraemer HC. The rol e and interpretation of pi[INVESTIGATOR_670590]. J Psychiatr Res. 2011;45(5):626 -629.
31. Loscalzo J. Pi[INVESTIGATOR_670591]. Circulation. 2009;119(1 3):1694 -1696.
32. Julious SA. Pi[INVESTIGATOR_670592]. Statistical Methods in Medical Research.
2016;25(3):995 -996.
33. Moore CG, Carter RE, Nietert PJ, Stewart PW. Recomm endations for planning pi[INVESTIGATOR_670593] h.Clin Transl Sci. 2011;4(5):332 -337.
34. Buch J.  Investigator Brouchure  ( ) Visual performance of
senofilcon A with and without a new UV/HEV -filter . August 2 021
35. Kalloniatis , Michael, and Charle s Luu. "Visual acuity." Webvisio n: The Organization
of the Retina and Visual System [Internet] (2007).
36. Buch J.  Clinical Study Report ) The Effects of Contact
[CONTACT_486760] -Blocker on Visual Function . August 21, 2019
37. Buch J.  Clinical Study Report ) The Effects of Contact
[CONTACT_253416]/HEV -Blocker on Visual Function . June 22, 2021
38. Kojima T, Hasegaw a A, Hara S, et al. Quantitative evaluation of night visi on and
correlation of refractive and topographical parameters with glare a fter orthokeratology.
Graefe's Archive for Clinical and Experimental Ophthalmology. 2011;249(10):1519 -
1526.
39. SAS Institut e Inc. 2016 SAS/STAT® 14.3 User’s Guide. Cary, NC: SAS Institute Inc.
40. Nixon A.  Clinical Study Protocol ) Evaluation of Daily
Disposable Toric Contact [CONTACT_670627] . March 29, 2021
41. Buch J.  Clinical Study Report ) Initial Evaluati on of
Investigational Lenses Manufactured on a New Production Line . October 08, 2019
42. ET Whittaker, Robinson G. The Trapezoidal and Parabolic Rules." The Calculus of
Observations: A Treatise on Nume rical Mathematics. 4th ed. Dover, [LOCATION_001]1967.
43. Kenward MG, Roger JH. Small Sample Infere nce for Fixed Effects from Restricted
Maximum Likelihood. Biometrics. 1997;53(3):983.
44. Korde Vea. Clinically Meaningful Contrast Sensitivity Difference for a He althy Eye.
Ophthal mology & Visual Science 2020; 61.[ADDRESS_905970] (HIPAA). Available at
https://www.hhs.gov/hipaa/for -professionals/privacy /index.html
CR-6463, v3.0
Page 84 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
46. Regulation (EU) 2017/745 of the European Pa rliament and of the Council of 5 April
2017 on medica l devices. Available at http://data.europa.eu/eli/reg/2017/7 45/2017 -05-
05
CR-6463, v3.0
Page 85 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
APPENDIX A: PATIENT REPORTED OUTCOMES (STUDY QUESTIONNAIRES)  
Not Applicable
CR-6463, v3.0
Page 86 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
APPE NDIX B: PATIENT INSTRUCTION GUIDE   
ThePatient Instruction Guide (PIG) will be provided separ ately.
CR-6463, v3.0
Page 87 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
APPENDIX C: PACKAGE INSERT (APPROVED PRODUCT)  
1-Day ACUVUE OASYS®with HydraLuxe™
CR-6463, v3.0
Page 88 of 182JJVC CONFIDENTIAL
DESCRIPTION
ACUVUE OASYS® Brand Contact [CONTACT_32993] 1-Day and ACUVUE OASYS® 
Brand Contact [CONTACT_32993] 1-Day for ASTIGMATISM are soft (hydrophilic) 
contact [CONTACT_35538]™ Technology. They are available as spherical or toric lenses respectively. 
These lenses are made of a silicone hydrogel material containing an internal 
wetting agent, visibility tint, and UV absorbing monomer and are tinted blue using Reactive Blue Dye #4 to make the lenses more visible for handling.
A benzotriazole UV absorbing monomer is used to block UV radiation. The 
transmittance characteristics for these lenses are less than 1% in the UVB range of 280 nm to 315 nm and less than 10% in the UVA range of 316 nm to 380 nm 
for the entire power range.
Lens Properties:
The physical/optical properties of the lens are:
• Speciﬁ  c Gravity (calculated): 0.98 - 1.12
• Refractive Index: 1.42
• Light Transmission: 85% minimum• Surface Character: Hydrophilic• Water Content: 38%
• Oxygen Permeability:
VALUE METHOD
122 x 10
-11 (cm2/sec) 
(ml O2/ml x mm Hg) at 35°CFatt (boundary corrected, non-
edge corrected)
103 x 10-11 (cm2/sec) 
(ml O2/ml x mm Hg) at 35°CFatt (boundary corrected, edge corrected)
Lens Parameters:
• Diameter Range: 12.0 mm to 15.0 mm
• Center Thickness: varies with power
• Base Curve Range: 7.85 mm to 10.00 mm
• Spherical Power Range: -20.00D to [PHONE_565]D
• Cylinder Power Range: 0.25D to -10 00D
• Axis Range: 2.5° to 180°CR-6463, v3.0
Page 91 of 182JJVC CONFIDENTIAL
AVAILABLE LENS PARAMETERS
ACUVUE OASYS® Brand 1-Day with HydraLuxe™ Technology are 
hemispherical shells of the following dimensions:
Diameter: 14.3 mm
Center Thickness: 0.085 mm to 0.221 mm (varies with power)
Base Curve: 8.5 mm, 9.0 mm
Powers: -0.50D to -6.00D (in 0.25D increments)
-6.50D to -12.00D (in 0.50D increments)+0.50D to +6.00D (in 0.25D increments)+6.50D to +8.00D (in 0.50D increments)
ACUVUE OASYS® Brand 1-Day with HydraLuxe™ Technology for 
ASTIGMATISM  are hemitoric shells of the following dimensions:
Diameter: 14.3 mm
Center Thickness: 0.075 mm to 0.172 mm (varies with power)
Base Curve: 8.5 mm
Powers: +0.00D to -6.00D (in 0.25D increments)
Cylinders: -0.75D, -1.25D, -1.75D, -2.25D*Axis: 10° to 180° in 10° increments
*-2.25D cylinder is availble in 10°, 20°, 70°, 80°, 90°, 100°, 110°, 
160°, 170°, 180° axes only.
+0.25D to +4.00D (in 0.25D increments)
-6.50D to -9.00D (in 0.50D increments)Cylinders: -0.75D, -1.25D, -1.75DAxis: 10°, 20°, 70°, 80°, 90°, 100°, 110°, 160°, 
170°, 180°
CR-6463, v3.0
Page 92 of 182JJVC CONFIDENTIAL
TRANSMITTANCE CURVES
ACUVUE OASYS® 1-Day with HydraLuxe™ Technology  (senoﬁ  lcon A) 
Visibility Tinted with UV Blocker vs. 24 yr. old human cornea and 25 yr. old 
human crystalline lens. 
……. ACUVUE OASYS®  
1-Day with HydraLuxe™ Technology (senoﬁ  lcon A)*
_____ 24 YR. OLD HUMAN CORNEA
1
- - - - - 25 YR. OLD HUMAN CRYSTALLINE LENS
2
* The data was obtained from measurements taken through the central 3-[ADDRESS_905971] marketed lens (-9.00D lens, 0.075 mm center thickness).
1Lerman, S., Radiant Energy and the Eye, MacMillan, [LOCATION_001], 1980, p. 58, ﬁ  gure 2-21
2Waxler, M., Hitchins, V.M., Optical Radiation and Visual Health, CRC Press, Boca Raton, [LOCATION_012], 
1986, p. 19, ﬁ  gure 5 
WARNING: UV absorbing contact [CONTACT_35539], such as UV absorbing goggles or sunglasses because they do not completely cover the eye and surrounding area. The patient should continue to use UV absorbing eyewear as directed.
ACTIONS
In its hydrated state, the contact [CONTACT_13293], when placed on the cornea, acts as a refracting medium to focus light rays onto the retina.
The transmittance characteristics for these lenses are less than 1% in the 
UVB range of 280 nm to 315 nm han 10% in the UVA range of 316 nm to 380 nm for the entire power range.
CR-6463, v3.0
PJJVC CONFIDENTIAL
NOTE:  Long-term exposure to UV radiation is one of the risk 
factors associated with cataracts.  Exposure is based on a number of factors such as environmental conditions (altitude, geography, cloud cover) and personal factors (extent and nature of outdoor activities).  UV-Blocking contact [CONTACT_35540]. However, clinical studies have not been done to demonstrate that wearing UV-Blocking contact [CONTACT_35541][INVESTIGATOR_35457]. The Eye Care Professional should be consulted for more information.
INDICATIONS (USES)
ACUVUE OASYS® Brand Contact [CONTACT_32993] 1-Day with HydraLuxe™ 
Technology are indicated for daily disposable wear for the optical correction of refractive ametropia (myopia and hyperopia) in phakic or aphakic persons with non-diseased eyes who may have 1.00D or less of astigmatism.
ACUVUE OASYS® Brand Contact [CONTACT_32993] 1-Day with HydraLuxe™ Tech-
nology for ASTIGMATISM are indicated for daily disposable wear for the 
optical correction of refractive ametropia (myopia and hyperopia) in phakic 
or aphakic persons with non-diseased eyes who may have 0.50D to 3.00D of astigmatism.
These lenses contain a UV Blocker to help protect against transmission of 
harmful UV radiation to the cornea and into the eye.
CONTRAINDICATIONS (REASONS NOT TO USE) 
DO NOT USE these contact [CONTACT_35542]:
• Acute or subacute inﬂ  ammation or infection of the anterior chamber 
of the eye.
• Any eye disease, injury or abnormality that affects the cornea, 
conjunctiva, or eyelids.
• Severe insufﬁ  ciency of lacrimal secretion (dry eye)
CR-6463, v3.0  
Page 94 of 182JJVC CONFIDENTIAL
• Corneal hypoesthesia (reduced corneal sensitivity).
• Any systemic disease that may affect the eye or be exaggerated by 
[CONTACT_35543].
• Allergic reactions of ocular surfaces or adnexa that may be induced 
or exaggerated by [CONTACT_71186].
• Ocular irritation due to allergic reactions which may be caused by 
[CONTACT_35545] (i.e., rewetting drops) that contain chemicals or preservatives (such as mercury, Thimerosal, etc.) to which some people may develop an allergic response.
• Any active corneal infection (bacterial, fungal, protozoal, or viral).
• If eyes become red or irritated.
WARNINGS
Patients should be advised of the following warnings pertaining to 
contact [CONTACT_13279]:
EYE PROBLEMS, INCLUDING CORNEAL ULCERS, CAN DEVELOP 
RAPI[INVESTIGATOR_35458]; IF THE PATIENT EXPE-RIENCES:
• Eye Discomfort,
• Excessive Tearing,• Vision Changes,• Loss of Vision,• Eye Redness,• Or Other Eye Problems, 
THE PATIENT SHOULD BE INSTRUCTED TO IMMEDIATELY RE-
MOVE THE LENSES AND PROMPTLY CONTACT [CONTACT_35546].
• When prescribed for daily wear, patients should be instructed not 
to wear lenses while sleepi[INVESTIGATOR_007]. Clinical studies have shown that 
the risk of serious  is increased when lenses are worn overnight, and that the risk of ulcerative keratitis is greater for 
CR-6463, v3.0 JJVC CONFIDENTIAL
• The potential impact of these factors on the patient’s ocular health 
should be carefully weighed against the patient’s need for refractive 
correction; therefore, the continuing ocular health of the patient and lens performance on the eye should be carefully monitored by [CONTACT_71187].
• Patients who wear these lenses to correct presby[CONTACT_35553]-
vision may not achieve the best corrected visual acuity for either far or near vision. Visual requirements vary with the individual and should be considered when selecting the most appropriate type of lens for each patient.
• Fluorescein, a yellow dye, should not be used while the lenses are 
on the eyes. The lenses absorb this dye and become discolored. Whenever ﬂ  uorescein is used in eyes, the eyes should be ﬂ  ushed with a sterile saline solution that is recommended for in-eye use.
• Eye Care Professionals should instruct the patient to remove the 
lenses immediately if the eyes become red or irritated. 
Eye Care Professionals should carefully instruct patients about the following care regimen and safety precautions.
Handling Precautions:
• Before leaving the Eye Care Professional’s ofﬁ  ce, the patient should 
be able to promptly remove the lenses or should have someone 
else available who can remove the lenses for him or her. 
• DO NOT use if the sterile blister package is opened or damaged. 
• Always wash and rinse hands before handling lenses. Do not get 
cosmetics, lotions, soaps, creams, deodorants, or sprays in the 
eyes or on the lenses. It is best to put on lenses before putting on makeup. Water-based cosmetics are less likely to damage lenses than oil-based products. 
• DO NOT touch contact [CONTACT_35554] ﬁ  ngers or hands if the 
hands are not free of foreign materials, as microscopic scratches of the lenses may occur, causing distorted vision and/or injury to the eye.
• Carefully follow the handli n, removal, and wearing 
instructions in the “Patient Instruction Guide” for the prescribed 
CR-6463, v3.0
Page 97 of 182JJVC CONFIDENTIAL
wearing schedule and those prescribed by [CONTACT_35555].
• Always handle lenses carefully and avoid droppi[INVESTIGATOR_35459].
• Never use tweezers or other tools to remove lenses from the lens 
container unless speciﬁ  cally indicated for that use. Slide the lens up 
the side of the bowl until it is free of the container. 
• Do not touch the lens with ﬁ  ngernails. 
Lens Wearing Precautions:
• If the lens sticks (stops moving) on the eye, follow the recom-
mended directions in “Care for a Sticking (Non-Moving) Lens." The lens should move freely on the eye for the continued health of the eye. If non-movement of the lens continues, the patient should be instructed to immediately consult his or her Eye Care Professional.
• Never wear lenses beyond the period recommended by [CONTACT_71188].
• The patient should be advised to never allow anyone else to wear 
their lenses. They have been prescribed to ﬁ  t their eyes and to correct their vision to the degree necessary. Sharing lenses greatly increases the chance of eye infections.
• If aerosol products, such as hair spray, are used while wearing 
lenses, exercise caution and keep eyes closed until the spray has settled.
• Avoid all harmful or irritating vapors and fumes while wearing 
lenses. 
• Always discard lenses worn as prescribed by [CONTACT_35555]. 
Lens Care Precautions:  
• The patient should be informed that no cleaning or disinfection is 
needed when lenses are worn for daily disposable wear.  Patients should always dispose of lenses when removed and have spare lenses or spectacles available.
CR-6463, v3.0
Page 98 of 182JJVC CONFIDENTIAL
Other Topi[INVESTIGATOR_35460]:
• Always contact [CONTACT_35558]-
cine in the eyes. 
• Certain medications, such as antihistamines, decongestants, 
diuretics, muscle relaxants, tranquilizers, and those for motion 
sickness may cause dryness of the eye, increased lens awareness, or blurred vision. Should such conditions exist, proper remedial measures should be prescribed. Depending on the severity, this could include the use of lubricating drops that are indicated for use with soft contact [CONTACT_71189]. 
• Oral contraceptive users could develop visual changes or changes 
in lens tolerance when using contact [CONTACT_13276]. Patients should be cautioned accordingly. 
• As with any contact [CONTACT_13293], follow-up visits are necessary to assure 
the continuing health of the patient’s eyes. The patient should be instructed as to a recommended follow-up schedule. 
Who Should Know That the Patient is Wearing Contact [CONTACT_32993]?
• Patients should inform all doctors (Health Care Professionals) about 
being a contact [CONTACT_35560]. 
• Patients should always inform their employer of being a contact 
[CONTACT_35560]. Some jobs may require use of eye protection equip-ment or may require that the patient not wear contact [CONTACT_13276]. 
ADVERSE REACTIONS
The patient should be informed that the following problems may occur when wearing contact [CONTACT_13276]:
• The eye may burn, sting, and/or itch.
• There may be less comfort than when the lens was ﬁ  rst placed on 
the eye.
• There may be a feeling of something in the eye (foreign body, 
scratched area).
• There may be the potential for some temporary impairment due to CR-6463, v3.0
Page 99 of 182JJVC CONFIDENTIAL
peripheral inﬁ  ltrates, peripheral corneal ulcers, or corneal erosion. 
There may be the potential for other physiological observations, such as local or generalized edema, corneal neovascularization, corneal staining, injection, tarsal abnormalities, iritis, and conjuncti-vitis; some of which are clinically acceptable in low amounts.
• There may be excessive watering, unusual eye secretions, or 
redness of the eye.
• Poor visual acuity, blurred vision, rainbows, or halos around 
objects, photophobia, or dry eyes may also occur if the lenses are worn continuously or for too long a time.
The patient should be instructed to conduct a simple 3-part self-examina-tion at least once a day. They should ask themselves:
• How do the lenses feel on my eyes?
• How do my eyes look?• Have I noticed a change in my vision? 
If the patient reports any problems, he or she should be instructed to 
IMMEDIATELY REMOVE THE LENS. If the problem or discomfort stops, the patient should discard the lens and place a new fresh lens on the eye.
If after inserting the new lens, the problem continues, the patient should be 
directed to IMMEDIATELY REMOVE THE LENS AND CONTACT [CONTACT_35561].
The patient should be instructed NOT to use a new lens as self-treatment 
for the problem.
The patient should be advised that when any of the above symptoms oc-
cur, a serious condition such as infection, corneal ulcer, neovascularization, or iritis may be present. He or she should be instructed to seek immediate professional identiﬁ  cation of the problem and prompt treatment to avoid serious eye damage.
CR-6463, v3.0
Page 100 of 182JJVC CONFIDENTIAL
GENERAL FITTING GUIDELINES
A. Patient Selection
Patients selected to wear these lenses should be chosen based on: 
• Motivation to wear lenses 
• Ability to follow instructions regarding lens wear care
• General health 
• Ability to adequately handle and care for the lenses 
• Ability to understand the risk and beneﬁ  ts of lens wear
Patients who do not meet the above criteria should not be provided with 
contact [CONTACT_13276]. 
B. Pre-ﬁ  tting Examination
Initial evaluation of the patient should begin with a thorough case history 
to determine if there are any contraindications to contact [CONTACT_13279]. During 
the case history, the patient’s visual needs and expectations should be 
determined as well as an assessment of their overall ocular, physical, and 
mental health. 
Preceding the initial selection of trial contact [CONTACT_13276], a comprehensive 
ocular evaluation should be performed that includes, but is not limited to, 
the measurement of distance and near visual acuity, distance and near 
refractive prescription (including determining the preferred reading distance 
for presby[CONTACT_35562]), keratometry, and biomicroscopic evaluation. 
Based on this evaluation, if it is determined that the patient is eligible to 
wear these lenses, the Eye Care Professional should proceed to the lens 
ﬁ  tting instructions as outlined below. 
C. Initial Power Determination
A spectacle refraction should be performed to establish the patient’s 
baseline refractive status and to guide in the selection of the appropriate 
lens power. Remember to compensate for vertex distance if the refraction 
is greater than ±4.00D.
D. Base Curve Selection (Trial Lens Fitting)
The following trial lenses should be e ec ed for patients regardless of kera-
tometry readings. However, corneal curvature measurements should be 
performed to establish the patient’s baseline ocular status. CR-6463, v3.0  
Page 101 of 182JJVC CONFIDENTIAL
• ACUVUE OASYS® 1-Day: 8.5 mm/14.3 mm
• ACUVUE OASYS® 1-Day for ASTIGMATISM: 8.5 mm/14.3 mm
The trial lens should be placed on each of the patient's eyes and evaluated 
after the patient has adjusted to the lenses.  
1. Criteria of a Properly Fit Lens 
A properly ﬁ  t lens will center and completely cover the cornea (i.e., no limbal exposure), have sufﬁ  cient movement to provide tear exchange under the contact [CONTACT_35563], and be comfortable. The lens should move freely when manipulated digitally with the lower lid, and then return to its properly centered position when released.
2. Criteria of a Flat Fitting Lens 
A ﬂ  at ﬁ  tting lens may exhibit one or more of the following characteris-tics: decentration, incomplete corneal coverage (i.e., limbal exposure), excessive movement with the blink, and/or edge standoff. If the lens is judged to be ﬂ  at ﬁ  tting, it should not be dispensed to the patient.
3. Criteria of a Steep Fitting Lens 
A steep ﬁ  tting lens may exhibit one or more of the following charac-teristics: insufﬁ  cient movement with the blink, conjunctival indentation, and resistance when pushing the lens up digitally with the lower lid. If the lens is judged to be steep ﬁ  tting, it should not be dispensed to the patient.
If the initial trial base curve is judged to be ﬂ  at or steep ﬁ  tting, the alternate base curve, if available, should be trial ﬁ  t and evaluated after the patient has adjusted to the lens. The lens should move freely when manipulated digitally with the lower lid, and then return to a properly centered position when released. If resistance is encountered when pushing the lens up, the lens is ﬁ  tting tightly and should not be dispensed to the patient.
E. Final Lens Power (Spherical)
A spherical over-refraction should be performed to determine the ﬁ  nal lens power after the lens ﬁ  t is judged acceptable. The spherical over-refraction should be combined with the trial lens power to determine the ﬁ  nal lens prescription. The patient should e good visual acuity with the correct lens power unless there is excessive residual astigmatism.
CR-6463, v3.0
2JJVC CONFIDENTIAL
Figure 1
You’ll need a slit lamp biomicroscope with a 1 to 2 mm 
parallelepi[INVESTIGATOR_35462] ﬁ  tted to the eye. There are a number of techniques you can use to improve the visibility of the 6 o’clock mark. Using a parallelepi[INVESTIGATOR_35463]ﬁ  cation (10x or 15x), slowly pan down the lens, looking just below the direct illumination at the retroilluminated area. Backlighting the mark this way should make it more visible. Sometimes manipulating the lower lid may be necessary to uncover the mark.
2. Observe Lens Rotation and Stability
Observe the position and stability of the “bottom” mark. It usually stabilizes at the 6 o’clock position. If it does, calculation of the lens power will be straightforward. The 6 o’clock position is not a “must”; however, the absolute requirement is that the axis position be stable and repeatable.
The mark may stabilize somewhat left or right (drift) of the vertical 
meridian and still enable you to ﬁ  t a toric lens for that eye, as long as the lens always returns to the same “drift axis” position after settling. The deviation can be compensated for in the ﬁ  nal prescription. Your objective is to ensure that whatever position the initial lens assumes near 6 o’clock, this position must be stable and repeatable. With full eye movement or heavy blink, you may see the marks swing away, but they must return quickly to the original stable position. If the lens does not return quickly, you may need to select a different lens.
3. Assessing Rotation
Imagine the eye as a clock dial and every hour represents a 30° interval. If the orientation mark of the initial lens stabilizes somewhat left or right of the vertical position, the ﬁ  nal lens will orient on the eye with the same deviation. You can use an axis reticule in the slit lamp or use a line-scribed lens in a spectacle trial frame to measure or estimate the “drift angle” of the cylinder axis.
To compensate for this “drift”, measure or estimate the “drift”, then 
add or subtract it from the refractive axis to determine the correct cylinder axis. Use the LARS (Left Add, Right Subtract) method to determine which direction to compensate.
CR-6463, v3.0
Page 104 of 182JJVC CONFIDENTIAL
B. Final Lens Power 
When the diagnostic lens has its axis aligned in the same meridian 
as the patient’s refractive axis, a spherocylindrical over-refraction may be performed and visual acuity determined. However, in the case of crossed axes, such as when the diagnostic lens axis is different from the spectacle cylinder axis, it is not advisable to perform a full spherocylindrical over-refraction because of the difﬁ  culty in computing the resultant power. A spherical over-refraction without cylinder refraction may be performed. 
If the required cylinder correction falls between two available cylinder 
powers, it is recommended to prescribe the lower cylinder power lens. See below for instructions on how to determine the ﬁ  nal lens power.
1. For the Sphere
If sphere alone or combined sphere and cylinder Rx > ±4.00D, 
compensate for vertex distance. If sphere alone or combined sphere and cylinder Rx ≤ ±4.00D, vertex compensation is not necessary.
2. For the Cylinder
Adjust the axis by [CONTACT_35564]. Choose a cylinder that is ≤ 0.50D from the refractive cylinder.
3. Case Examples
Example [ADDRESS_905972] (spectacle) refraction:
O.D. -2.50D / -1.25D x 180° 20/20O.S. -2.00D / -1.00D x 180° 20/20
Choose a diagnostic lens for each eye with axis 180°. Place 
the lens on each eye and allow a minimum of 3 minutes for it to equilibrate, based on the patient’s initial response to the lens. If the lens has not yet stabilized, recheck until stable.
Check the orientation of the axis mark. If the bottom axis mark 
is in the 6 o’clock position on both eyes, choose the appropriate cylinder as listed previously. If the lens has not yet stabilized, recheck until stable.
Here is the Rx Prescribed:
O.D. -2.50D / -1.25D x 180°O.S. -2.00D / -0.75D x 180°
CR-6463, v3.[ADDRESS_905973] (spectacle) refraction:O.D. -3.00D / -1.00D x 90° 20/20O.S. -4.75D / -2.00D x 90° 20/20
Choose diagnostic lenses of -3.00D / -0.75D x 90° for the right 
eye and -4.50D / -1.75D x 90° for the left eye, the nearest lenses available to the spherical power, cylinder power, and axis needed. For the left eye, since the manifest refraction called for -4.75D, compensating for vertex distance the sphere is reduced by 0.25D to -4.50D. The cylinder power will be -1.75D. Place the lens on each eye and allow a minimum of 3 minutes for it to equilibrate, based on the patient's initial response to the lens. If the lens has not yet stabilized, recheck until stable. 
Right Eye
The orientation mark on the right lens rotates left from the 6 
o’clock position by 10° and remains stable in this position. Compensation for this rotation should be done as follows: 
Compensate the 10° axis drift by [CONTACT_35565].
Here is the Rx Prescribed:
O.D. -3.00D / -0.75D x 100°
Left Eye
The orientation mark on the left lens rotates right from the 6 
o’clock position by 10° and remains stable in this position. 
Compensate for the 10° axis drift by [CONTACT_35566]. 
Here is the Rx Prescribed: 
O.S. -4.50D / -1.75D x 80°
If vision is acceptable, perform a slit lamp examination to assess 
adequate ﬁ  t (centration and movement). If ﬁ  t is acceptable, dispense the lenses instructing the patient to return in one week for reassessment (see dispensing and follow-up information in PATIENT MANAGEMENT).
All patients should be supplied with a copy of the PATIENT INSTRUCTION GUIDE for these lenses. Copi[INVESTIGATOR_35461].acuvue.com.
CR-6463, v3.[ADDRESS_905974] adequately 
corrected distance and near visual acuity in each eye. The amblyopic patient or the patient with signiﬁ  cant astigmatism (greater than 1.00D) in one eye may not be a good candidate for monovision correction with these lenses.
Occupational and environmental visual demands should be 
considered. If the patient requires critical vision (visual acuity and stereopsis), it should be determined by [CONTACT_71190]. Monovision contact [CONTACT_35568]:
• visually demanding situations such as operating potentially 
dangerous machinery or performing other potentially hazardous 
activities; and
• driving automobiles (e.g., driving at night). Patients who cannot 
meet state driver's licensing requirements with monovision correction should be advised to not drive with this correction, OR may require that additional over-correction be prescribed.
2. Patient Education
All patients do not function equally well with monovision correc-tion. Patients may not perform as well for certain tasks with this correction as they have with spectacles (multifocal, bifocal, trifocal, readers, progressives). Each patient should understand that monovision, as well as other presby[CONTACT_35569], can create a vision compromise that may reduce visual acuity and depth perception for distance and near tasks. Therefore, caution should be exercised when the patient is wearing the correction for the ﬁ  rst time until they are familiar with the vision provided in visually chal-lenging environments (e.g., reading a menu in a dim restaurant, driving at night in rainy/foggy conditions, etc.). During the ﬁ  tting process, it is necessary for the patient to realize the disadvantages as well as the advantages of clear near vision and straight ahead and upward gaze that monovision contact [CONTACT_35570].
CR-6463, v3.0
Page 107 of 182JJVC CONFIDENTIAL
B. Eye Selection
1. Ocular Preference Determination Methods
Generally, the non-dominant eye is corrected for near vision. The 
following two methods for eye dominance can be used.
Method 1:  Determine which eye is the “sighting eye.” Have the 
patient point to an object at the far end of the room. 
Cover one eye. If the patient is still pointing directly at the object, the eye being used is the dominant (sighting) eye.
Method 2:  Determine which eye will accept the added power with 
the least reduction in vision. Place a hand-held trial lens equal to the spectacle near ADD in front of one eye and then the other while the distance refractive error correction is in place for both eyes. Determine whether the patient functions best with the near ADD lens over the right or left eye.
2. Other Eye Selection Methods
Other methods include the "Refractive Error Method" and the "Visual Demands Method."
Refractive Error MethodFor anisometropic correction, it is generally best to ﬁ  t the more 
hyperopic (less myopic) eye for distance and the more myopic (less hyperopic) eye for near.
Visual Demands Method
Consider the patient’s occupation during the eye selection process 
to determine the critical vision requirements. If a patient’s gaze for near tasks is usually in one direction, correct the eye on that side for near.
Example: A secretary who places copy to the left side of the desk 
will function best with the near lens on the left eye.
C. Special Fitting Characteristics
1. Unilateral Vision Correction
There are circumstances where only one contact [CONTACT_35571]. As an example, an ent would only require a near 
lens, whereas a bilateral myope would require corrective lenses on 
CR-6463, v3.0
Page 108 of 182JJVC CONFIDENTIAL
both eyes.
Examples: A presby[CONTACT_35572] a +1.75D ADD 
would have a +1.75D lens on the near eye and the other eye left without correction. 
A presby[CONTACT_35573] a +1.50D ADD who is -2.50D 
myopic in the right eye and -1.50D myopic in the left eye may have the right eye corrected for distance and the left uncorrected for near.
2. Near ADD Determination
Always prescribe the lens power for the near eye that provides optimal near acuity at the midpoint of the patient’s habitual reading distance. However, when more than one power provides optimal reading performance, prescribe the least plus (most minus) of the powers.
3. Trial Lens Fitting
A trial ﬁ  tting is performed in the ofﬁ  ce to allow the patient to experience monovision correction. Lenses are ﬁ  t according to the GENERAL FITTING GUIDELINES for base curve selection described in this Package Insert.
Case history and standard clinical evaluation procedure should 
be used to determine the prognosis. Determine the distance correction and the near correction. Next determine the near ADD. With trial lenses of the proper power in place, observe the reaction to this mode of correction.
Allow the lenses to settle for about [ADDRESS_905975] the patient look at you. Assess the patient’s reaction to distance vision under these circumstances. Then have the patient look at familiar near objects such as a watch face or ﬁ  ngernails. Again assess the reaction. As the patient continues to look around the room at both near and distance objects, observe the reactions. Only after these vision tests are completed should the patient be asked to read print. Evaluate the patient’s reaction to large print (e.g., typewritten copy) at ﬁ  rst and then graduate to newsprint and ﬁ  nally smaller type sizes.
After the patient’s perform er the above conditions 
is completed, tests of vis and reading ability under 
CR-6463, v3.0
Page 109 of 182JJVC CONFIDENTIAL
Monovision ﬁ  tting success can be improved by [CONTACT_35576]:
• Reverse the distance and near eyes if a patient is having trouble 
adapting.
• Reﬁ  ne the lens powers if there is trouble with adaptation. 
Accurate lens power is critical for presby[CONTACT_35577].
• Emphasize the beneﬁ  ts of clear near vision and straight ahead 
and upward gaze with monovision.
The decision to ﬁ  t a patient with monovision correction is most appropriately left to the Eye Care Professional in conjunction with the patient after carefully considering the patient’s needs.
All patients should be supplied with a copy of the PATIENT 
INSTRUCTION GUIDE for these lenses. Copi[INVESTIGATOR_35461].acuvue.com.
PATIENT MANAGEMENT
Dispensing Visit
Each sterile lens is supplied in a foil-sealed plastic package containing 
buffered saline solution with methyl ether cellulose. To remove the lens from the container, peel back the foil seal, place a ﬁ  nger on the lens, and slide the lens up the side of the bowl of the lens package until it is free of the container.
• Evaluate the physical ﬁ  t and visual acuity of the lens on each eye.
• Teach the patient how to apply and remove his or her lenses.
• Explain daily disposable lens wear and schedule a follow-up examination.
• Provide the patient with a copy of the PATIENT 
INSTRUCTION GUIDE for these lenses. Copi[INVESTIGATOR_35461].acuvue.com.
REVIEW THESE INSTRUCTIONS WITH THE PATIENT SO THAT HE 
OR SHE CLEARLY UNDERSTANDS THE PRESCRIBED WEARING AND REPLACEMENT SCHEDULES.
Follow-Up Examinations
Follow-up care (necessary to ensure continued successful contact [CONTACT_13279]) should include routine periodic progress examinations, management of speciﬁ  c problems, if any, and a th the patient of the wear schedule, daily disposable modality, and proper lens handling procedures. 
CR-6463, v3.0
P2JJVC CONFIDENTIAL
Recommended Follow-up Examination Schedule (complications 
and speciﬁ  c problems should be managed on an individual patient 
basis):
1. One week from the initial lens dispensing to patient
2. One month post-dispensing
3. Every three to six months thereafter 
NOTE: Preferably, at the follow-up visits, lenses should be worn for at least 
six hours.
Recommended Procedures for Follow-up Visits:
1. Solicit and record patient’s symptoms, if any.
2. Measure visual acuity monocularly and binocularly at distance and 
near with the contact [CONTACT_13276].
3. Perform an over-refraction at distance and near to check for residual 
refractive error.
4. With the biomicroscope, judge the lens ﬁ  tting characteristics (as 
described in the GENERAL FITTING GUIDELINES) and evaluate 
the lens surface for deposits and damage.
5. Following lens removal, examine the cornea and conjunctiva with 
the biomicroscope and ﬂ  uorescein (unless contraindicated).
• The presence of vertical corneal striae in the posterior central 
cornea and/or corneal neovascularization is indicative of 
excessive corneal edema.
• The presence of corneal staining and/or limbal-conjunctival 
hyperemia can be indicative of an unclean lens, a reaction to solution preservatives, excessive lens wear and/or a poorly ﬁ  tting lens.
• Papi[INVESTIGATOR_35465]/or damaged lens.
6. Periodically perform keratometry and spectacle refractions. The 
values should be recorded and compared to the baseline meas-
urements.
If any observations are abnormal, use professional judgment to 
alleviate the problem and restore the eye to optimal conditions. If CR-6463, v3.0  
Page 112 of 182JJVC CONFIDENTIAL
the criteria for successful ﬁ  t are not satisﬁ  ed during any follow-up 
examinations, repeat the patient’s trial ﬁ  tting procedure and reﬁ  t 
the patient.
WEARING SCHEDULE
The wearing schedule should be determined by [CONTACT_35578].   
Regular checkups, as determined by [CONTACT_35578], are also extremely important.
Patients tend to overwear the lenses initially. The Eye Care Professional 
should emphasize the importance of adhering to the initial maximum wear-ing schedule.  Maximum wearing time should be determined by [CONTACT_35579]’s physiological eye condition, because individual response to contact [CONTACT_35580].
The maximum suggested wearing time for these lenses is:
Day Hours
[ADDRESS_905976] spare lenses or spectacles available.
Basic Instructions
• Always wash, rinse, and dry hands before handling contact [CONTACT_13276].
• Do not use saliva or anything other than the recommended solutions 
for lubricating or rewetting lenses. Do not put lenses in the mouth.
• Eye Care Professionals may recommend a lubricating/rewetting solution which can be used to wet (lubricate) lenses while they are being worn to make them more comfortable. 
Care for a Sticking (Non-Moving) Lens
If the lens sticks (stops moving), the patient should be instructed to apply 
a few drops of the recommended lubricating or rewetting solution directly to the eye and wait until the lens begins to move freely on the eye before removing it. If non-movement of the lens continues after a few minutes, the patient should immediately consult the Eye Care Professional.
EMERGENCIES
The patient should be informed that if chemicals of any kind (household products, gardening solutions, laboratory chemicals, etc.) are splashed into the eyes, the patient should: FLUSH EYES IMMEDIATELY WITH TAP WATER AND IMMEDIATELY CONTACT [CONTACT_35581] A HOSPI[INVESTIGATOR_35466]. 
HOW SUPPLIED
Each UV-blocking sterile lens is supplied in a foil-sealed plastic package containing buffered saline solution with methyl ether cellulose. The plastic package is marked with the following: 
• ACUVUE OASYS
® 1-Day: base curve, power, diameter, lot number, 
and expi[INVESTIGATOR_320]
• ACUVUE OASYS® 1-Day MATISM: base curve, power, 
diameter, cylinder, axis, lot and expi[INVESTIGATOR_35467]-6463, v3.0
Page 114 of 182JJVC CONFIDENTIAL
REPORTING OF ADVERSE REACTIONS
All serious adverse experiences and adverse reactions observed in 
patients wearing these lenses or experienced with these lenses should be reported to:
[COMPANY_012] Vision Care, Inc.
[ADDRESS_905977]
Jacksonville, FL [ZIP_CODE]
[LOCATION_003]
Tel: [PHONE_564]
www.acuvue.com
CR-6463, v3.0
Page 115 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
APPENDIX D:   
 Lens Fitting Characteristics
 Subject Report ed Ocular Symptoms/Problems
Determination of Distance Spherocylindrical Refractions
 Biomicroscopy Scale
Distance and Near Visual Acuity E valuation
CR-6463, v3.0
Page 117 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
 LENS FITTING CHARACTERISTICS  
 
CR-6463, v3.0
Page 118 of 182JJVC CONFIDENTIAL
Title:                          Lens Fitting Characteristics
Document Type:  
Document Number :  Revi sion Number:  5
Page 1of 5CR-6463, v3.0
Page 119 of 182JJVC CONFIDENTIAL
Title:                          Lens Fitting Characteristics
Document Type:  
Document Number :  Revi sion Number:  5
Page 2of 5            
       
CR-6463, v3.0
Page 120 of 182JJVC CONFIDENTIAL
Title:                          Lens Fitting Characteristics
Document Type:  
Document Number :  Revi sion Number:  5
Page 3of 5CR-6463, v3.0
Page 121 of 182JJVC CONFIDENTIAL
Title:                          Lens Fitting Characteristics
Document Type:  
Document Number :  Revi sion Number:  5
Page 4of 5CR-6463, v3.0
Page 122 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
 SUBJECT REPORTED OCULAR SYMPTOMS/PROBLEMS  
 
CR-6463, v3.0
Page 124 of 182JJVC CONFIDENTIAL
Title:                         Subject Reported Ocular Symptoms/Problems
Document Type:  
Document Number :  Revi sion Number:  3
Page 1of 1  
  
            
CR-6463, v3.0
Page 125 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
 DETERMINATION OF DISTANCE SPHEROCYLINDRICAL 
REFRACTIONS  
 
CR-6463, v3.0
Page 126 of 182JJVC CONFIDENTIAL
Title:                        Determination of Dist ance Spherocylindrical Refractive Error
Document Type:  
Document Number :  Revi sion Number:  5
Page 1of 5  
CR-6463, v3.0
Page 127 of 182JJVC CONFIDENTIAL
Title:                        Determination of Dist ance Spherocylindrical Refractive Error
Document Type:  
Document Number :  Revi sion Number:  5
Page 2of 5CR-6463, v3.0
Page 128 of 182JJVC CONFIDENTIAL
Title:                        Determination of Dist ance Spherocylindrical Refractive Error
Document Type:  
Document Number :  Revi sion Number:  5
Page 3of 5CR-6463, v3.0
Page 129 of 182JJVC CONFIDENTIAL
Title:                        Determination of Dist ance Spherocylindrical Refractive Error
Document Type:  
Document Number :  Revi sion Number:  5
Page 4of 5CR-6463, v3.0
Page 130 of 182JJVC CONFIDENTIAL
Title:                        Determination of Dist ance Spherocylindrical Refractive Error
Document Type:  
Document Number :  Revi sion Number:  5
Page 5of 5CR-6463, v3.0
Page 131 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
 BIOMICROSCOPY SCALE  
 
CR-6463, v3.0
Page 132 of 182JJVC CONFIDENTIAL
Title: Biomicroscopy Scale
Document Type:
Document Number: Revision Number:  9
CR-6463, v3.0
Page 133 of 182JJVC CONFIDENTIAL
Title: Biomicroscopy Scale
Document Type:
Document Number: Revision Number:  9
CR-6463, v3.0
Page 134 of 182JJVC CONFIDENTIAL
Title: Biomicroscopy Scale
Document Type:
Document Number: Revision Number:  9
CR-6463, v3.0
Page 135 of 182JJVC CONFIDENTIAL
Title: Biomicroscopy Scale
Document Type:
Document Number: Revision Number:  9
  
CR-6463, v3.0
Page 137 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
 DISTANCE AND NEAR VISUAL ACUITY EVALUATION  
 
CR-6463, v3.0
Page 138 of 182JJVC CONFIDENTIAL
Title:  Distance and Near Snellen Visual Acuity Evaluation
Document Type:  
Document Number :  Revi sion Number:  4
Page 1of 4CR-6463, v3.0
Page 139 of 182JJVC CONFIDENTIAL
Title:                        Distance and Near Snellen Visual Acuity Evaluation
Document Type:  
Document Number :  Revi sion Number:  4
Page 2of 4CR-6463, v3.0
Page 140 of 182JJVC CONFIDENTIAL
Title:                        Distance and Near Snellen Visual Acuity Evaluation
Document Type:  
Document Number :  Revi sion Number:  4
Page 3of 4CR-6463, v3.0
Page 141 of 182JJVC CONFIDENTIAL
Title:                        Distance and Near Snellen Visual Acuity Evaluation
Document Type:  
Document Number :  Revi sion Number:  4
Page 4of 4CR-6463, v3.0
Page 142 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
APPENDIX E: ACCEPTANCE OF THE METROPSIS SYSTEM  
 
 
CR-6463, v3.0
Page 143 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
CR-6463, v3.0
Page 144 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
CR-6463, v3.0
Page 145 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
CR-6463, v3.0
Page 146 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
CR-6463, v3.0
Page 147 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
APPENDIX G: GUIDANCE FOR INITIAL LENS POWER  
CR-6463, v3.0
Page 149 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
APPENDIX H: METROPSIS WORK AID  
 
CR-6463, v3.0
Page 150 of 182JJVC CONFIDENTIAL
DĞƚƌŽƉƐŝƐtŽƌŬŝĚZͲϲϰϲϯsĞƌƐŝŽŶϭ͘ϬϮϬ WĂŐĞϮŽĨϭϳ
CR-6463, v3.0
Page 152 of 182JJVC CONFIDENTIAL
DĞƚƌŽƉƐŝƐtŽƌŬŝĚZͲϲϰϲϯsĞƌƐŝŽŶϭ͘ϬϮϬ WĂŐĞϯŽĨϭϳCR-6463, v3.0
Page 153 of 182JJVC CONFIDENTIAL
DĞƚƌŽƉƐŝƐtŽƌŬŝĚZͲϲϰϲϯsĞƌƐŝŽŶϭ͘ϬϮϬ WĂŐĞϰŽĨϭϳCR-6463, v3.0
Page 154 of 182JJVC CONFIDENTIAL
DĞƚƌŽƉƐŝƐtŽƌŬŝĚZͲϲϰϲϯsĞƌƐŝŽŶϭ͘ϬϮϬ WĂŐĞϱŽĨϭϳCR-6463, v3.0
Page 155 of 182JJVC CONFIDENTIAL
DĞƚƌŽƉƐŝƐtŽƌŬŝĚZͲϲϰϲϯsĞƌƐŝŽŶϭ͘ϬϮϬ WĂŐĞϲŽĨϭϳCR-6463, v3.0
Page 156 of 182JJVC CONFIDENTIAL
DĞƚƌŽƉƐŝƐtŽƌŬŝĚZͲϲϰϲϯsĞƌƐŝŽŶϭ͘ϬϮϬ WĂŐĞϳŽĨϭϳCR-6463, v3.0
Page 157 of 182JJVC CONFIDENTIAL
DĞƚƌŽƉƐŝƐtŽƌŬŝĚZͲϲϰϲϯsĞƌƐŝŽŶϭ͘ϬϮϬ WĂŐĞϴŽĨϭϳCR-6463, v3.0
Page 158 of 182JJVC CONFIDENTIAL
DĞƚƌŽƉƐŝƐtŽƌŬŝĚZͲϲϰϲϯsĞƌƐŝŽŶϭ͘ϬϮϬ WĂŐĞϵŽĨϭϳCR-6463, v3.0
Page 159 of 182JJVC CONFIDENTIAL
DĞƚƌŽƉƐŝƐtŽƌŬŝĚZͲϲϰϲϯsĞƌƐŝŽŶϭ͘ϬϮϬ WĂŐĞϭϬŽĨϭϳCR-6463, v3.0
Page 160 of 182JJVC CONFIDENTIAL
DĞƚƌŽƉƐŝƐtŽƌŬŝĚZͲϲϰϲϯsĞƌƐŝŽŶϭ͘ϬϮϬ WĂŐĞϭϭŽĨϭϳ
CR-6463, v3.0
Page 161 of 182JJVC CONFIDENTIAL
DĞƚƌŽƉƐŝƐtŽƌŬŝĚZͲϲϰϲϯsĞƌƐŝŽŶϭ͘ϬϮϬ WĂŐĞϭϮŽĨϭϳCR-6463, v3.0
Page 162 of 182JJVC CONFIDENTIAL
DĞƚƌŽƉƐŝƐtŽƌŬŝĚZͲϲϰϲϯsĞƌƐŝŽŶϭ͘ϬϮϬ WĂŐĞϭϯŽĨϭϳCR-6463, v3.0
Page 163 of 182JJVC CONFIDENTIAL
DĞƚƌŽƉƐŝƐtŽƌŬŝĚZͲϲϰϲϯsĞƌƐŝŽŶϭ͘ϬϮϬ WĂŐĞϭϰŽĨϭϳCR-6463, v3.0
Page 164 of 182JJVC CONFIDENTIAL
DĞƚƌŽƉƐŝƐtŽƌŬŝĚZͲϲϰϲϯsĞƌƐŝŽŶϭ͘ϬϮϬ WĂŐĞϭϱŽĨϭϳCR-6463, v3.0
Page 165 of 182JJVC CONFIDENTIAL
DĞƚƌŽƉƐŝƐtŽƌŬŝĚZͲϲϰϲϯsĞƌƐŝŽŶϭ͘ϬϮϬ WĂŐĞϭϳŽĨϭϳ




CR-6463, v3.0
Page 167 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
APPENDIX I: METROPSIS AN D GLARE SOURCE SPECIFICS  
 
CR-6463, v3.0
Page 168 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
 
CR-6463, v3.0
Page 169 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
APPENDIX J: GUIDELINES FOR COVID -19 RISK MITIGATION  
 
CR-6463, v3.0
Page 170 of 182JJVC CONFIDENTIAL
Title: Guidelines for COVID-19 Risk Mitigation
Document Type:
Document Number: Revision Number: 5
 
1.0 PURPOSE
The purpose of this doc ument is to provide guidelines for the re -opening or initiation of clinical study sites 
participating in Johnson &Johnson Vision Care, Inc. ( JJVCI )clinical studies dur ing the COVID -19
pandemic.
2.0 SCOPE
This document provides guidelines for Johnson &Johnson Vision Care ( JJVCI )to address the potential risks 
from COVID -[ADDRESS_905978] from the date of approval through th e date of retirement of this Work 
Instruction. At a minimum ,this Work Instruction will be  reviewed and updated on a quarterly basis, a s
appropriate.
NOTE:  Re-opening of s ites outside of the US will be evaluated on a country by [CONTACT_19605].
3.0 DEFINITIONS
American Academy of Optometry (AAO): The American Academy of Optometry is an organization of 
optometrists based in Orlando, Flor ida. Its goal is to maintain and enhance excellence in optometric 
practice, by [CONTACT_35582]. The AAO holds an annual 
meeting, publishes a monthly scientific journal, give s credentials to optometrists  through the fellowship 
process and publishes position statements.
American Optometric Association ( AOA ):The American Optom etric Association, founded in 1898, is 
the leading authority on quality care and an advocate for our nation's health, representing more than 44,000 
Doctors of Optometry (O.D.), optometric professionals, and optometry students. Doctor of Optometry take 
a leading role in patient care with respect to eye and vision care, as well as general health and well -being. 
As primary health care providers, Doctor of Optometry have extensive, ongoing training to examine, 
diagnose, treat and manage ocular disorders, diseas es and injuries and sys temic diseases that manifes t in the 
eye. The American Optometric Asso ciation is a federation of state, stud ent, and armed forces optometric 
associations. Through these affiliations, the AOA serves me mbers consisting of optometrists, students of 
optometry, paraoptometric assistants a nd technicians. The AOA and its aff iliates work to provide the public 
with quality vision and eye care.
Center sfor Disease Control and Prevention (CDC ):The Centers for Disease Control and Prevention is a 
national public health institute in the [LOCATION_002]. It is a [LOCATION_002] federal agency, under the 
Department of Health and Human Services, and is headquartered in Atlanta, Georgia.
COVID -19: Current outbreak of respi[INVESTIGATOR_35468] a novel coronavirus. The virus has been 
named “S ARS -CoV -2” and the disease it causes has been  named “Coronavirus Disease 2019” (COVID -
19).
Clinical Study: Voluntary research studies cond ucted in people and designed to answer specific questions 
about the safety or effectiveness of drugs, vaccines, other therapi[INVESTIGATOR_014], or new ways of using existing 
treatments. May also be called clinical trials, studies, research, trials, or protocols.
Clinical Study Site: Location where a clinical study is  conducted, such as a doctor’s office, university, or 
laboratory. Clin ical studies are conducted by [CONTACT_35583](s) responsible for the 
conduct of the clinical study at a study site. If a stud y is conducted by a team of individuals, the 
Investigator is the responsible leader  of the team and may be called the Principal Investigator.
Clinical Operations Manager (COM) :The [COMPANY_012] Vision Care ( JJVC I) individual 
responsible for the overall ma nagement of a clinical trial.
CR-6463, v3.0
Page 171 of 182JJVC CONFIDENTIAL
Title: Guidelines for COVID-19 Risk Mitigation
Document Type:
Document Number: Revision Number: 5
 
Monitor: Anindividual designated to oversee the progress of a clinical study and ensure that it is 
conducted, recorded, and reported in accordance with  the protocol, Standard Operating Procedures (SOPs), 
Good Clinical Practice (GCP), and ap plicable regulatory requirements.
Medical Safety Officer (MSO) :Physician who has prim ary accountability in their product portfolio for 
product health and safety, and who serves as an independent medical voice for patient safety.
Safety Management Team (SMT) :A cross -functional, collaborative team responsible for review, 
assessment and eva luation of medical safety data arising from any source throughout the product life cycle.
4.[ADDRESS_905979] the health ,safety
and well -being of particip ants and site staff. If, at an y time, a participant’s safety is considered to be at risk, 
study intervention will be discontinued, and study follow -up will be conducted as outlined in the protocol.  
During the COVID -19 pandemic, the additional risks liste d below need to be considered for study participants 
and study personnel :
Additional Risks Related to the COVID -19 Pandemic:
xThe p ossible transmission of the Coronavi rusinfection and consequent complications, beyond the 
risk of adverse events due to the investigational device and/or procedures .
xThe risk may be higher in an op tometric clinical study because of the close contact [CONTACT_126133] (since the investigator
must make the measurements close to the subject’s face) and, in addition the need for multiple 
follow -up visits/exams which may expose the subject to other patients and/or healthcare 
professionals who might be transmitting the virus ,even if they do not have symptoms.
xPotential disruptions to the study may be nece ssary due to current or future pandemic -related 
emergency restrictions, which may lead to delays in scheduled follow -up visits.
xSubjects experienc ingan adverse event related to contact [CONTACT_126134] -19restrictions. In this event, a ll assessments that can be conducted virtually will be 
completed by [CONTACT_126135], including
anunscheduled visit, up to discontinuation from the study , as appropriate .
Ifastudy subject is found to  have contracted COVID -19during participation in astudy, he/she will be 
discontinued from the study and follo wed until COVID -19Adverse Event (AE) resolution.
To help minimize the above potential risks, JJVCI recommend reviewing/complying with local, state, 
and governmental guidance for COVID -19 risks. 
JJVC Iwill provide the following study specific documents wi th language pertaining to COVID -19 risks:
4.1.1 Informed Consent :
Will include information concerning the study -associated risks relate d to the COVID -19 pandemic 
in bold font and/or boxed on the first page of the I nformed Consent document:
CR-6463, v3.0
Page 172 of 182JJVC CONFIDENTIAL
Title: Guidelines for COVID-19 Risk Mitigation
Document Type:
Document Number: Revision Number: 5
 
STUDY ASSOCIATED RISKS RELATED TO COVID -19 (CORONAVIRUS ) PANDEMIC
It is important to note that this  study will be conducted, at leas t in part, during the COVID -[ADDRESS_905980] for you. Thi s is particularly important for this 
study due, in part, to the closeness of the doctor during the study examinations. 
The potential effects of the dise ase are not fully known, at th is time, and may include long -term serious health 
consequences. In sever e cases, this may result in hospi[INVESTIGATOR_5478]/or death. Based on current knowledge from the 
Center sfor Disease Control and Prevention (CDC), those at high -risk for severe illness from COVID -19 include 
older adults and people w ith underlying medical cond itions. 
During this study, all appropriate measur es will be taken to minimize risks in cluding the use of personal protective 
equipment such as masks and glov es, as well as proper sanitization. This is in conformance to guidance from the 
CDC, local healt h departments, and the state and county in which the study doctor’s office  is located. However, 
these measures may not completely eliminate th e risks associated with contracting COVID -19. 
If you are found to have contracted COVID -19 or feel ill with flu -like symptoms during pa rticipation in the study, 
you will not be permitted to continue in -office study follow -up visits ,but you will receive instructions and your 
condition will be monitored by [CONTACT_35586]/or study staff.
4.1.[ADDRESS_905981](Attachment -B):
Will include COVID -[ADDRESS_905982] JJVCI clinical 
studies. The risk controls are consistent with CDC, AOA, AAO Guidance. The Princip al
Investigator will review/sign the study specific  checklist prior to the Site Initiation Meeting.
4.1.3 Protocol Compliance Investigator(s) Signature [CONTACT_3490] :
Will include a statement indicating thatthePrincipal Investigator ( PI)agrees to conduct the study 
in compliance with all local, state, and governmental guidance’s for COVID -[ADDRESS_905983] read the sugges ted guidance provided by [CONTACT_19610] -19 risk mitigation,
(COVID -19 Work Instruction in the Appendix of this protocol) .I agree to conduct this study in 
compliance with local, state, governmental guidance for COVID -19 risks.
4.1.4 Study Site Initiation Training Slides :
Will include sug gestions to help mitigate potential transmission of COVID -19. Suggestions may 
include maintaining social distan cing in the clinical site by [CONTACT_126138] p atients,
wearing proper PPEs, frequ ent disinfection, and installing shields on the s lit lamp and other 
applicable equipment .
5.[ADDRESS_905984] VISITS
Potential disruptions to the study may be nece ssary due to current or future pandemic -related emergency 
restrictions .  Possible disruption of the study as a result of COVID -19 control measures may lead to delays 
in scheduled follow -up visits.
Subjects may be delayed in being seen for study follow up visit(s), for example due to COVID -[ADDRESS_905985]’s concerns or fears about COVID -19risk.When appropriate , the remote 
assessment willbe conducted to the extent possible.  Discussions with the subject during remote assessments 
may include:
CR-6463, v3.0
Page 173 of 182JJVC CONFIDENTIAL
Title: Guidelines for COVID-19 Risk Mitigation
Document Type:
Document Number: Revision Number: [ADDRESS_905986] the sponsor’s responsible 
medical monitor to discuss initial plan s for study intervention and follow -up. The medical monitor will 
notify the Safety Management Team of a ny subject(s) that have reported “COVID -19”, “ Asymptomatic 
COVID -19”, or “Suspected COVID -19” adverse events within [ADDRESS_905987] as a result of the COVID -19 pandemic will be summarized in the 
clinical study report.  
COVID -19 screening procedur es that may be mandated by [CONTACT_299317].
Monitoring Visits
When on -site monitoring by [CONTACT_19613] ,the sponsor’s site monitor w ill contact [CONTACT_19614]. In such cases, on -site monitoring visits will resume when feasible, with
increased frequency to address th e source data verification backlog.
Even with staffing lim itations during this COVID -[ADDRESS_905988] process. When conditions permit, all 
parties involved in this clinical  trial should communicate relevant information in a timely  manner so that 
all relevant parties remain  sufficiently informed.
6.1.1 Study Site Initiation:  
During the period that this Work Instruction is in effect , Site Initiation Meetings and training of 
study site staff will be conducted remotely .The JJVCI study team will conduct tr aining via Skype, 
Zoom, Microsoft Teams or similar software as well as utilize online training materials ,as applicable.  
Study site training will be documented utilizing Site Initiation Report
On-site visits may be considered when, for example, hands -on training or evaluation of site facilities 
is required. While on site, the Clinical Research Associate ( CRA )will follow all local, state, and 
governmental policies for COVID -19 Risk Mitigation, including socia l distancing, wearing of PPE, 
etc. as applicable for the lo cation of the study site.
6.1.2 Interim Monitoring Visits (if applicable) :
During the period that this Work Instruction is in effect, Interim Monitoring On-site v isits will be 
kept to a minimum and include only those tasks that the CRA cannot perform remotely (e.g., source 
document verification , test article reconciliation, etc.) .
To ensure data integrity during the conduct of all JJVC studies, clinical study teams will follow the 
study specific Clinical Monitoring Plan
While on site, the CRA will follow all local, state,  and governmental policies for COVID -19 Risk 
Mitigation, including social distancing, wearing of PP E, etc. as applicable for the location of the 
study site.
CR-6463, v3.0
Page 175 of 182JJVC CONFIDENTIAL
Title: Guidelines for COVID-19 Risk Mitigation
Document Type:
Document Number: Revision Number: 5
 
6.1.3 Study Site Closure:  
During the period that this Work Instruction is in effect, the durati on of the Study Site Closure Visit 
willbe lim ited to tasks that the CRA cannot perform re motely (e.g., source document verification, 
test article final rec onciliation and return, etc.).  
CR-6463, v3.0
Page 176 of 182JJVC CONFIDENTIAL
Title: Guidelines for COVID-19 Risk Mitigation
Document Type:
Document Number: Revision Number: 5
 
Attachment A: Study Site Correspondenc e
XXXX XX, 2020
Re: COVID -19 Mitigation Plan, << CR-xxxx /protocol title>>
Dear <<Princip alInvestigator>> and Study Team,
Coronavirus (COVID -19) has impacted several communities and busi ness activities over the past several months. 
While we work toward the successful  conduct of clinical studies, our commitme nt continues to be the safety of 
patients, healthcare professi onals, and to our communities. 
Therefore, we would like to share th e following revisions/additions related to the above referenced Johnson & 
Johnson Vision Care company sponsored clinical tria l(s) you are currently working on or considering participation 
within. 
Protocol:
xGuidelines for COVID -19 Risk Mitigation provided in the Appendix section.
Protocol Signature [CONTACT_3490]:
xWill include a statement indicating the Princip al Investigator agrees to conduct the study in compliance 
with all local, state, and gove rnmental guidelines for COVID -19 risk mitigation.
Informed Consent:
xWill include information concerning the study -associated risks related to the COVID -19 pandemic in bold 
font and/or boxed on the first page of the Informed consent document.
COVID -[ADDRESS_905989] for Clinical Studies:
xWill include COVID -[ADDRESS_905990] with your respective 
[COMPANY_012] cl inical study team ( Clinical Research Associate ( CRA ),Lead CRA or Study Managers).  
Thank you for your continued engageme nt, collaboration, and dedication to your study subjects during this 
challenging time. 
Please file this letter in your s ite file study correspondence. 
CR-6463, v3.0
Page 177 of 182JJVC CONFIDENTIAL
Title: Guidelines for COVID-19 Risk Mitigation
Document Type:
Document Number: Revision Number: 5
 
RESOURCE LINKS
US Resource Links 
xOSHA Training
https://www.osha.gov/SLTC/covid -19/controlprevention.html
Personal Protective Equipment ( PPE)Training
CDC: https://www.cdc.gov/coronavirus/2019 -ncov/hcp/using -ppe.html
xI&R Training
ACUVUE®LensAssist: https://www.acuvue.com/lensassist    
xClinic Preparedness Guides
CDC: https://www.cdc.gov/coronavirus/2019 -ncov/hcp/clini c-preparedness html
AOA: https://aoa.uberflip.com/i/1240437 -aoa-guidance -for-re-opening -practices -covid·19/1?m4=
American Optom etric Association: https://www.aoa.org/optometry -practice -reactivation -preparedness -
guide
xln-Office Disinfection of Multi -Patient Use Diagnostic Contact [CONTACT_19609]://www.gpli.info/wp -content/uploads/2020/03/2020 -01-15-in-office -disinfecting -of-diagnostic -
lenses.pdf
OUS Resource Links 
xUpdates on local regulations in Hong Kong
https://www.coronavirus.gov hk/eng/index.html
xResumption of optical services in England: Letter from Matt Neligan and Poonam Sharma
https://www.england nhs.uk/coronavi rus/wp -content/uploads/sites/52/2020/04/C0601 -reopening -of-optical -
services -letter -17-june-2020.pdf
xNHS Optical Letter
https:/ /www.england nhs.uk/coronavirus/wp -content/uploads/sites/52/2020/04/C0127 -optical -letter -1-april-
2020.pdf
xThe College of Opto metrists primary eye care COVID -19 guidance: Red phase
https://www.college -optometrists.org/the -college/media -hub/news -listing/coronavirus -covid -19-guidance -
for-optometrists .html
xThe College of Optometrists COVID -19: College updates
https://www.college -optometrists.org/t he-college/media -hub/news -listing/coronavirus -2019 -advice -for-
optometrists.html# CollegeGuidelines
xInfection Control Guidelines. (n .d.). Retrieved from Canadian  Association Of Optometrists: 
https://opto.ca/sites/defau lt/files/resources/docume nts/infection_control_guidelines_2016.pdf
xInfection prevention an d control for COVID -19: Interim guidance for outpatient and ambulatory care 
settings. (2020, May 23 May). Retrieved from Govern ment of Canada: https ://www.canada.ca/en/public -
health/services/ diseases/2019 -novel -coronavirus -infection/guidance -documents/interim -guidance -
outpatient -ambulatory -care-settings html
CR-6463, v3.0
Page 180 of 182JJVC CONFIDENTIAL
Title: Guidelines for COVID-19 Risk Mitigation
Document Type:
Document Number: Revision Number: 5
 
xInformation for Members On Coronavirus (COVID -19). (n.d.). Retrieved from Canadian Association Of
Optometrists: 
https://opto.ca/sites/def ault/files/resources/documents/information_for_members_on_coronavirus.pdf
xCoronavirus (COVID -19) resources for health professionals, in cluding aged care providers, pathology 
providers and health care managers. (2020, September 24). Retrieved from Australian Government 
Department of Health:
https://www health.gov.au/res ources/collections/coronavirus -covid -19-resources -for-health -professionals -
including -aged -care-providers -pathology -providers -and-health -care-managers
 
xEnvironmental Cleaning and Disinfection Principles for COVID -19. (n.d.). Retrieved from Australian 
Government Department of Health: 
https://www.health.gov.au/s ites/default/files/documents /2020/03/environmental -cleaning -and-disinfection -
principles -for-covid -19.pdf
xInfection control guidelines and advice. (n .d.). Retrieved from Optometry Australia : 
https://www.optometry.org.au/practice -professional -support/coronavirus -covid -19-what -optometrists -need -
to-know/covid -19-clinical -advice/infection -control -guideline s-and-advice/
 
CR-6463, v3.0
Page 181 of 182JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
PROTOCOL COMPLIANCE INVEST IGATOR(S) SIGNATURE [CONTACT_93962]: CR-6463Visual performance of senofilcon A with and without a new 
UV/HEV -filter 
Version and Date: 3.[ADDRESS_905991] read and un derstand the protoc ol specified above and agree on its content.  
I agree to conduc t this study according to ISO 141 55:2020 ,1and ICH guidelines ,2the Declaratio n of 
Helsinki ,3[LOCATION_002] (US) Code of Federal Regulations (CFR) ,4and the pertinent individual country 
laws/regulations and to comply with its obligat ions, subje ct to ethical and safety considerations. The 
Principal Investigator [INVESTIGATOR_53470] f or ensuring that all clinical site personnel, including Sub -
Investigators adhere to all IC H2regulations and GCP guidelines reg arding clinical trials during and 
after study completion.
I will assure that no dev iation from or changes to the protocol will take place without prior agreement 
from the Sponsor and documented ap proval from the Institutional Review Bo ard (IRB), except wh ere 
necessary to eliminate an immediate hazard(s) to the trial participants.
I am r esponsible for ensuring that all clinical site personnel including Sub -Investigators adhere to all 
ICH2regulations and GCP gui delines regarding clinical trials during and after study completion.
All clinical s ite personnel involved in the conduct of this study have completed Human Subjects 
Protection Trai ning. 
I agree to ensure that all clinical site personnel involved in the conduct of this study are informed about 
their obligations in meeting the above comm itments.
I shall not disclose the information containe d in this protocol or any results obtained from this study 
without written authorization.
I have read the suggested guidance provided by [CONTACT_19610] -19 risk mitigation, 
(COVID -19 Wor k Instruction in the Appendix Jof this protocol). I agree to conduct this study in 
compliance wi th local, state, governmental guidance for COVID -19 risks.
Principal 
Investigator:
[INVESTIGATOR_19540] (Printed)
Institution/Site:
Institution/Site Name
[CONTACT_16277]/Site Address
CR-6463, v3.0
Page 182 of 182JJVC CONFIDENTIAL